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ABSTRACT
ALTERNATIVE MRNA SPLICING REDEFINES THE LANDSCAPE OF COMMONLY
DYSREGULATED GENES ACROSS THE ACUTE MYELOID LEUKEMIA PATIENT POPULATION

Osvaldo D. Rivera
Kristen W. Lynch & Yoseph Barash
Most genes associated with acute myeloid leukemia (AML) are mutated in less than
10% of patients, suggesting that alternative mechanisms of gene disruption contribute to
this disease. Here, I investigate pre-mRNA splicing events with significant variation and
striking coregulation across distinct AML cohorts. I find that most splicing events are
expected to alter the expression of a subset of AML-associated genes independent of
known somatic mutations. In particular, I highlight that aberrant splicing triples the
number of patients with reduced functional EZH2 protein compared with that predicted
by somatic mutation alone. In addition, I unexpectedly find that transcripts encoding the
nonsense-mediated RNA decay factor DHX34 exhibit widespread alternative splicing in
sporadic AML, resulting in a premature stop codon that phenocopies the loss-of-function
germline mutations observed in familial AML. The identification of DHX34 splicing event
that functionally downregulates the nonsense-mediated mRNA degradation (NMD)
pathway motivated a query of splicing variations in an additional set of related NMD
factors. Although no particular study has highlighted genetic mutations in the queried
NMD factors, I find significant variation at the level of mRNA splicing that is expected to
have further deleterious effects across AML patients. Together, these results demonstrate
that classical mutation analysis underestimates the burden of functional gene disruption
in AML and highlight the importance of assessing the contribution of alternative splicing
to gene dysregulation in human disease.
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PREFACE
Acute myeloid leukemia (AML) is an aggressive hematologic cancer in which
malignant myeloid precursor cells impair hematopoiesis and induce bone marrow failure.
The molecular heterogeneity of AML patients has been recognized for over 35 years now.
Most genes associated with AML are mutated in less than 10% of patients, suggesting that
alternative mechanisms of gene disruption may contribute to this disease. Although a
significant body of work exists detailing the pathology and molecular basis of distinct
leukemias, very few studies exist that characterize dysregulation at the level of RNA
processing. The maturation of messenger RNA (mRNA) molecules requires distinct
process and are largely coordinated through alternative splicing patterns produced by the
spliceosome machinery. About 95% of transcribed multi exon genes are spliced in more
than one way to give rise to multiple mature transcript varieties from a single genetic locus.
This in turn generates complex transcriptomic and proteomic diversity that has been
overlooked by most studies of AML and cancer. Furthermore, it wasn’t until recently that
technologies facilitated the high-throughput quantification of alternative mRNA splicing.
There is a growing body of evidence that underscores the importance of dysregulating
alternative mRNA splicing in supporting an oncogenic molecular profile and generating
splice variants that phenocopy the effects of genetic mutations. The following dissertation
documents analyses that shed light on patterns of alternative splicing within genes
associated with AML and demonstrate that alternative splicing provides an additional
mechanism by which gene function is disrupted in AML. These results demonstrate that
classical mutation analysis underestimates molecular burden of functional gene
disruption in AML and highlight the importance of assessing the contribution of
alternative splicing to gene dysregulation in human disease.
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CHAPTER I
Introduction
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Introduction
RNA Biology
Pre-mRNA Transcription and Splicing. RNA transcription is an early essential the
step in the process of successful gene expression. In eukaryotes, transcription is executed
by one of three RNA polymerases. Specifically, protein-coding genes are transcribed by
RNA polymerase II (RNAPII) into premature-mRNA (pre-mRNA) in a strand-specific
manner. RNAPII transcription initiates at millions of positions in the mammalian genome
from core promoters that have an array of closely located transcription-start sites (TSSs)
with different rates of initiation [1]. RNAPII moves along genes that are up to millions of
base pairs in length and generates pre-RNA as it transcribes the gene region. The
transcription machinery and the nascent pre-mRNA interact with various small-nuclear
ribonucleoproteins (snRNPs) and RNA-binding proteins (RBPs) to secure the maturation
of pre-mRNA. The C-terminal domain tail of RNAPII regulates the activity of RNA-protein
complexes involved in RNA processing and maturation steps such as 5’-end capping,
splicing, 3’-end processing, editing, folding, nuclear export and decay of mRNA [2].
Splicing of mRNA precursors is therefore a co-transcriptional event required for the
maturation of almost all human mRNAs and is a key step in the regulation of expression
of many genes.
During the process of pre-mRNA splicing, a collection of snRNPs that make up the
spliceosome bind to conserved RNA sequence features known as splice-sites and define
intron/exon boundaries across gene transcripts. Specifically, the major spliceosome is a
megadalton complex composed of multiple distinct snRNPs (U1, U2, U4, U5, U6) [3]. The
RNA splicing mechanics of more than 99% of protein-coding transcripts are essentially
regulated by the major spliceosome while fewer than 1,000 introns (i.e., ∼0.3%) are
removed by the minor spliceosome, which uses distinct snRNPs (U11, U12, U4atac, and
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U6atac) but shares U5 and most proteins with the major spliceosome [4]. The process of
pre-mRNA splicing involves the stepwise interaction between the spliceosome and a set of
sequence motifs known as the core splicing signals, namely the 5′ splice site (5′ss), the 3′
splice site (3′ss), the branch point sequence (BPS), and the polypyrimidine tract (Py-tract).
The recruitment and activity of the spliceosome constitute the usage of both core splicing
signals and secondary cis-acting splicing RNA elements (SREs) followed by a cascade of
molecular remodeling events that can involve more than 100 others auxiliary RBPs known
as “splicing factors” [5]. Additionally, transcription elongation rates driven by gene
architecture and chromatin features can in turn influence splice site identification by the
spliceosome and modulate splicing patterns [6].
The earliest steps of the metazoan spliceosome assembly are built around the exon
junction boundaries in a process called “exon definition”. The inclusion of most exons is
largely under control by the inherent strength or weakness of the flanking core splicing
signals as well as combinatorial binding of auxiliary splicing factors to distinct SREs. [7; 8;
9; 10; 11]

(Figure 1.1A). The context and positional relationship between core splicing

signals and SREs are crucial for the exon-definition process, particularly across gene
transcripts with complex architecture that undergo tightly regulated alternative splicing
events. Accordingly, sequences comprising this second class of cis-acting RNA elements
can be subdivided into splicing ‘silencers’ and ‘enhancers’ that often overlap across exon
and intron regions. Depending on the location and function of the particular SRE, it is
categorized as an exonic (ESE/ESI) or intronic (ISE/ISS) splicing enhancer or silencer
(Figure 1.1A). Most studies highlight that the 200–300 nucleotides adjacent to the
observed splice sites, harbor the most relevant sequence features for the modulation of
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alternative splicing [12; 13]. However, in some cases, there is evidence that distal intronic
SREs ( > 500 nt. from the exon being spliced) are able to facilitate splicing regulation [14].
After binding to the pre-mRNA has occurred, the spliceosome transitions into
subcomplexes that direct the RNA splicing reaction via ATP-dependent conformational
rearrangements and molecular interactions with the coupled auxiliary splicing factors [3].
Initially, the U1 snRNP binds to the 5’ss and the U2 auxiliary factor coupled with U2
snRNP binds to the Py-tract/3’ss to form the pre-spliceosome and positions the ends of
the intron into a catalytic center. Subsequently, the U4/U6.U5 tri-snRNPs activate the prespliceosome and reconfigure the interactions between the snRNPs and pre-mRNA splice
sites. The splicing reaction itself is a two-step transesterification reaction catalyzed by
U6/U2 snRNA complex that resembles a self-splicing ribozyme (Figure 1.2A). In the first
step (step I), the 2′-hydroxyl of the BPS adenosine carries out a nucleophilic attack on the
phosphodiester bond of the 5′ss guanosine, yielding a 5′ exon with a free 3′-hydroxyl and
a branched intron lariat that is attached to the 3′ exon. In the second step (step II), the 3′hydroxyl of the 5′ exon attacks the first nucleotide downstream of the 3′ss guanosine,
thereby splicing the 5′ss to the 3’-exon and releasing the excised intron lariat
Over 95% of human multi-exon genes can express functionally different RNA
transcript isoforms by alternatively including or excluding particular exons, with at least
80% of these changes altering the protein-coding potential of said transcript [15; 11]. Thus,
alternative pre-mRNA splicing enables vast proteomic diversity from a limited number of
genes. Furthermore, there is a growing body of evidence that coordinated alternative
splicing networks regulate important physiological functions in different developmental
processes in humans, including tissue and organ development [16]
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Figure 1.1 – RNA Splicing Reaction, Core Splicing Signals and Alternative
splicing types. (A) RNA splicing reaction depicted as a sequential transesterification
reaction initiated by nucleophilic attack of the 5’ splice site by the branch point adenosine
in the intron being spliced out. This is followed by a second attack from the 3’ hydroxyl
group of the 5’ss to the 3’ ss that results in the formation of an intron lariat plus the spliced
product. (B) Spliceosome binding to core splicing signals (BPS, Py-tract, 3’ss and 5’ss) and
cis-acting SREs – namely exonic and intronic splicing enhancers (ESE/ISE) and silencers
(ESS/ISS) sequence features of the pre-mRNA. (Adapted from Mariana & Swanson 2016)
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A Code for Alternative Splicing. The cascade of molecular rearrangements that make
up the assembly and sub-complex transitions of the spliceosome as well as the recruitment
of auxiliary splice factors represent potential points of regulation for the alternative
inclusion of particular regions of the pre-mRNA sequence. In alternative splicing events,
recognition and joining of a 5’ss-3’ss pair by the spliceosome are in competition with at
least one other 5’ss-3’ss pair. Common outcomes of alternative splicing include skipping
or inclusion of a cassette exon, alternative 5′ or 3′ splice site choice lengthening or
shortening an exon, mutually exclusive exons, alternative first or last exon, and intron
retention (Figure 1.2A-B). In practice, splicing events may involve several splice site
choices yielding complex patterns of alternative splicing (Figure 1.2C). Indeed, complex
splicing events are common in diverse metazoans, making up at least a third of observed
splicing events in human and mouse [17]. Complex splicing events are less likely to have a
‘dominant’ splice junction (inclusion > 60%). An analysis of datasets across different
tissues and developmental stages revealed that complex splicing events have more evenly
distributed inclusion levels with no dominant junction as well as an enrichment for
regulated splicing of a third junction (inclusion > 10%), suggesting regulation and possible
functionality of multiple isoforms [17].
Figure 1.2 – Effects of Alternative Splicing Types (A) Cassette Exons differentially
includes one particular exon. The binary inclusion on the alternative exon can promote
the expression of an alternative protein isoform or insert a premature termination codon
(PTC) and tag the transcript for nonsense mediate RNA decay (NMD). C1 and C2 are
common nomenclature for the constitutive exons involved in a binary splicing choice while
‘A’ depicts the alternative sequence. (B) Other Common binary alternative splicing event
types include intron retention (IR), Mutually exclusive exon inclusion, alternative 5’ss and
3’ss, alternative first and last exon, alternative 5’UTR and 3’UTR (C) Complex alternative
splicing events have more than two junctions that can be differentially spliced together.
Examples include multi-exon skipping events as well as distinct splicing event types that
have overlapping splicing junction usage.
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Combinatorial knockdown of RBPs reveal differences in the recognition of splice
sites by selectively influencing the recruitment of the spliceosome [18]. These phenomena
underscore how the spliceosome has inherently weak affinity to the RNA substrate, and
that additional interactions from multiple auxiliary splicing factors are required to
maintain the integrity and fidelity of the pre-mRNA splicing process. Most regulatory
contexts of alternative splicing events arise from auxiliary RBPs competitively binding to
overlapping sets of cis-acting SREs along the transcript. RBPs bind SRE motifs
discriminately but also, with a range of redundancy, allowing transcripts to ensure the
ability to bind the necessary RBPs required to adhere to the coding standards and global
cell regulatory constraints. Gene transcripts are regulated by a discrete subset of RBPs,
and each RBP typically regulates several other hundred splicing events, thereby installing
alternative splicing networks that allow cells to readily respond to molecular stimuli [10; 11;
19; 20].

Therefore, even modest changes in the abundance or activity of individual RBPs can

result in altered splicing patterns involving hundreds of different transcripts. Ultimately,
the decision of which splice sites are used to produce a particular splicing pattern is
determined by the complex interplay of a pool of trans-acting RBPs that competitively
bind along exons and introns in a combinatorial fashion thereby influencing the
spliceosome through a variety of molecular mechanisms and cellular pathways [21]
In humans, classically identified families of trans-acting splicing factors and
regulatory RBPs can be divided into three major classes: Serine/arginine-rich (SR)
proteins, canonical heterogeneous nuclear ribonucleoproteins (hnRNPs), and other
hnRNP-like proteins [22]. SR proteins are defined by containing at least one RRM-type
RNA-binding domain and a serine–arginine (SR)-rich domain that facilitates homotypic
interactions with core components of the spliceosome as well as other SR proteins [23;11].
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Although not always the case, the SR protein family is typically recognized as exonic
splicing enhancers. For example, a particular SR protein could promote exon inclusion by
binding to exons and recruiting U1 snRNP to the 5ʹ splice site and U2 auxiliary factor
(U2AF) to the 3ʹ splice site through protein–protein interactions in early steps of
spliceosome assembly [24; 25]. Conversely, the hnRNP protein family was defined by a copurification experiment that revealed them as abundant nuclear factors [26], and are thus
more structurally diverse, containing RRM-, KH, and RGG-type RNA-binding domains as
well as low-complexity regions. Lastly, the hnRNP-like family of proteins were identified
more recently, and these share sequence similarity to the canonical hnRNPs, but exhibit
more tissue-specific and temporal-restricted expression patterns [27; 28].

Splicing Mis-regulation is an Oncogenic Driver. A comprehensive pan-cancer
analyses revealed that tumors have on average 20% more alternative splicing events than
matched healthy tissues [29;

30].

The regulatory parameters intrinsic to the pre-mRNA

splicing process allow for mis-regulation to occur via multiple avenues. Changes to the
motif sequence of core splicing signals and SREs are one way by which individual splicing
events may be altered. Indeed, an increasing number of genetic mutations found in
cancers that have previously been annotated as missense or nonsense actually alter
splicing fidelity and affect gene expression by hindering splicing of individual introns
and/or generating new splice sites [31; 32; 33]. Conversely, trans-acting genetic alterations
to RBPs and splicing factors would typically result in wide-spread alterations to RNAprocessing patterns. As it happens, many cancers harbor mutations in genes encoding
splicing factors, further supporting the fact that disruptions to splicing homeostasis drive
cancer progression [22]. Change-of-function mutations have been typically observed in
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splice factor genes, thereby changing the sequence specify of the RNA-binding domain and
producing subsets of aberrant splicing events. Splice factor mutations are also typically
observed to be heterozygous, suggesting that homozygous alterations are not tolerated by
the cancer cell.
Alternative mRNA splicing allows for switches in protein isoforms in the absence
of permanent changes in the cell's genetic content, and without changes in transcriptional
activity [34]. Furthermore, small changes in the level of protein abundance of distinct RBPs
are capable of effecting large changes in alternative splicing patterns. Thus, when
perturbed, gene expression levels of RPBs and splicing factors are potentially capable of
promoting an oncogenic molecular profile independent of genetic alterations. Indeed, SR
and hnRNP proteins have been shown to act as oncoproteins when overexpressed in the
correct cellular context. For example, modest overexpression of the SR splicing factor 1
(SRSF1; also known as ASF and SF2) is pro-tumorigenic in cancers, including lung, colon
and breast cancer [35; 36; 37]. Additionally, downregulation of SRSF1 gene expression has
been observed in a subset of AML patients with altered splicing patterns [38], although
more work needs to be done to demonstrate oncogenicity. Conversely, other splicing
factors may also act as tumors suppressors. For example, HNRNPK (among other genes)
lies in chromosome 9 locus which is recurrently deleted (-9q) in acute myeloid leukemias,
and therefore a portion of patients have significantly reduced hnRNP K protein expression
[39]. Mouse studies found that deletion of one Hnrnpk allele results in genomic instability
and the formation of transplantable hematopoietic neoplasms. The reduced hnRNP K
expression promoted proliferation via attenuated p21 activation and activated STAT3
signaling, as well as halted differentiation through downregulated C/EBP levels. [40].
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Cancer cells may also leverage alternative splicing to facilitate disease relapse. One
study of acute lymphoblastic leukemia (ALL) patients found that alternative splicing of
CD19, particularly the skipping of exon 2, removed from the epitope targeted by the
chimeric antigen receptor immunotherapy (CART-19). The alternatively spliced transcript
translated a truncated CD19 peptide that promoted disease relapse [41]. Additionally, the
plasticity of RNA splicing allows for the cancer cells to modulate normal splicing programs
and generate different transcript variants which mediate chemotherapy resistance. For
example, there is evidence that relapsed ALL patient blasts may be skipping exon 11 in
FPGS to disrupt the function of folylpolyglutamate synthase, an enzyme involved in the
intracellular retention of folate antagonist drugs used to commonly used to treat ALL
patients [42]. Thus, profiling alternative RNA splicing status within a particular tumor
sample unequivocally provides information that aids in the assessment of oncogenicity
effected by molecular changes to the transcriptome.

High-Throughput Quantification of Alternative pre-mRNA Splicing. Splicing
regulation has been traditionally studied either at the level of full gene isoforms or through
the specification of alternative splicing ’events’. The elucidation of splicing regulation has
benefitted tremendously from experimental methods such as in vitro splicing assays [43].
However, the sheer complexity of splicing regulatory mechanisms warranted the
development of high-throughput methods that accurately map transcriptome-wide
variations in alternative pre-mRNA splicing. In particular, RNA-sequencing (RNA-Seq)
technology produces millions of read sequences derived from gene transcripts that can be
leveraged to produce models of alternative splicing events. Splicing quantification
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algorithms utilize read sequences that span over splice junctions to create a ‘splicegraph’
that models the inclusion ratios of a particular splicing event.
Determining whether two distant exons originate from the same mRNA transcript
is a problem that can be addressed by long-read sequencing technologies (e.g., PacBio,
Oxford Nanopore). However, long read sequencing is currently very costly, and is unable
to properly resolve small variations (<10nt) between isoforms, highlighting detection
limits of the technology [44]. Also, sequencing errors, alignment and amplification artifacts
posing as novel splice sites in long-reads present a challenge for many existing splicing
quantification tools, and thus studies have supplemented noisy long-read sequencing data
with short-read sequencing data to rescue reads with incorrect splice sites and facilitate
downstream analysis [45]. As discussed in the previous section, the maturation of premRNAs requires the polyadenylation of the 3’ end of the transcripts. Thus, sequencing of
polyadenylated RNA provides a robust catalog of transcripts expressed by most genes with
known function. The downside to using short-read RNA-seq data include potentially
limited coverage depth across genes expressed at low levels as well as bias towards
particular regions of the transcript. Specifically, oligo-dT priming and DNase
fragmentation are known to generate read bias towards the 3’ end of transcripts. However,
despite these challenges, short-read RNA-seq data produces a robust catalog of molecular
abundance for a particular gene transcript library which can be parsed to produce
quantitative models of alternative splicing (Figure 1.3).
Exon–exon junctions can be identified by the presence of the GT–AG dinucleotides
that flank splice sites and confirmed by the low expression of intronic sequences, which
are removed during splicing. A variety of computational methods for the high-throughput
quantification of alternative pre-mRNA splicing have been developed for short-read RNA-
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seq analysis, such as SUPPA [46], rMATS [47], MISO [48], SpliceTrap [49], rSeqDiff [50],
Cufflinks [51], FDM [52], DiffSplice [53], DEXSeq [54]. Initially, these algorithms had critical
limitations in detecting differential splicing and/or isoform proportion while accounting
for variability among replicates and could not handle large sample sizes. Initial algorithms
were also only capable of quantifying annotated binary splicing events. While useful, it is
evident that binary alternative splicing events fail to capture the full complexity of
spliceosome decisions [17]. To address the shortcomings of initial high-throughput splicing
modeling paradigms, Vaquero et al. developed the MAJIQ model (Modeling Alternative
Junction Inclusion Quantification), a framework that efficiently combines RNA-Seq data
with existing gene annotation and to enable the accurate detection, quantification, and
visualization of complex splicing variations across large numbers of experimental
conditions.
Unlike many of the aforementioned methods that only analyze known isoforms,
MAJIQ supplements known transcripts with de novo junctions inferred from the RNAseq data. The results of MAJIQ’s splicing quantification can be interactively visualized
with the VOILA package in a standard web browser. Importantly, the MAJIQ model
quantifies splicing events in terms of local splicing variations, or LSVs, that individually
represent substructures in the transcriptome. LSVs capture complex alternative splicing
events (Figure 1.2C), which were found to be more prevalent in human transcriptomes
(over 30%). An LSV is defined as a single exon alternatively joined to more than one RNA
segment. LSVs are visualized as splits (multiple edges) in a splicegraph where several
edges either come into or from a single exon, termed the reference exon. Junctions
involved in an LSV are quantified in terms of Percent Splicing Index (PSI, Y), a unit value
that represents the relative fraction of poly-A selected mRNA transcripts in which the
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aforementioned exon is joined to each of the alternative RNA segments (Figure 1.3).
MAJIQ can quantify LSVs within a single sample, as well compare two experimental
conditions with or without replicate groups through differential splicing analysis across
large heterogenous datasets. LSV quantification in a single condition is based on the
marginal PSI (Y) for each junction involved in the LSV, while the differential comparison
of experimental conditions is based on relative changes in Y (dPSI, DY). The MAJIQ
framework uses Bayesian modeling to report posterior Y and DY distributions for each
quantified LSV (Figure 1.3D). Importantly, MAJIQ empirical PSI estimates inferred
from RNA-seq data have achieved robust overall correlations (RY = 0.8, RDY = 0.95) with
splicing quantification done by radiolabeled RT-PCR in an analysis of datasets from
multiple tissues. Moreover, MAJIQ’s reproducibility of both binary and complex LSVs is
stable across varying read coverage depth, further underscoring the robustness of the
method. Notably, MAJIQ analyses have also indicated that including de-novo junctions
increases the number of differentially spliced LSVs that could be detected by around 30%.
Therefore, the reproducibility, accuracy and LSV detection power of the MAJIQ algorithm,
as well as its ad-hoc visualization tools, make a computational framework suitable for the
analyses of mis-regulated complex transcriptomes intrinsic to cancer.

14

Introduction

Figure 1.3 – High-Throughput Quantification of Alternative Splicing. (A)
Schematic of MAJIQ Splicing Event Identification and Quantification. RNA-seq data in
the form of aligned and sorted bam files is submitted alongside a genomic database of
annotated splicing events. The MAJIQ Build algorithm produces a collection of .sj files
that contain all of the quantified junctions for a particular sample alongside a splicegraph
database that collectively allows for the visualization of the splicing models that included
splicing decisions across all of the selected samples. (B) Quantification of Percent Splice
Index (PSI) using junction-spanning reads. The ratio of inclusion specific reads for a
particular junction is denoted by (PSI, Y). Differential inclusion of junctions is calculated
between samples and is denoted as deltaPSI (DY) (Adapted from Dvinge et al. 2016)
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Acute Myeloid Leukemia
AML disease heterogeneity. The formation of blood cellular compartments – namely
hematopoiesis – is a process settled in the bone marrow driven by a rare subpopulation of
self-renewing hematopoietic stem cells (HSCs). The molecular mechanisms driving the
proliferation and terminal differentiation of hematopoietic cell populations are mostly
conserved across mammals [55]. HSCs are endowed with regulated quiescence and selfrenewal capabilities that preserve the multipotency of dividing cells and sustain the
generation of adequate levels of blood cellular compartments over a human’s lifetime [55;
56; 57].

When this delicate balance of differentiation, proliferation, and self-renewal is

disrupted, it results in the development of hematopoietic disorders. Leukemias are liquid
tumors that specifically arise from the transformation of hematopoietic stem cells and
progenitor cells in the bone marrow. Thus, the malignant transformation of healthy bone
marrow cells is a multistep process that involves the acquisition of molecular lesions that
collectively impede normal cell programs and result in the generation of neoplastic clones
with dysregulated developmental and proliferative properties [58; 59].
Acute myeloid leukemia (AML) is a class of hematologic cancer characterized by
the aggressive clonal proliferation of abnormally differentiated myeloid precursor cells
(Figure 1.4) [60]. According to World Health Organization (WHO) Classification system
guidelines, the diagnosis of AML requires that myeloblasts constitute more than 20% of
the bone marrow or circulating peripheral blood white cell population [61]. Additionally,
the percentage of blood cell compartments such as promyelocytes, monoblasts,
promonocytes and megakaryoblasts are included in the classification process, and are
used to define the various AML subtypes. Cells obtained from AML patients – namely
AML blasts – often have striking morphological similarities to normal HSCs and often
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share similar cell surface marker profiles. Monoclonal antibodies targeting cluster of
differentiation (CD) cell surface proteins are restricted to cells committed to myeloid
differentiation (e.g., CD11b, CD13, CD14, CD33), but are found in untransformed cells and
are thus not representative of a leukemia-specific prognostic signature or unique to
different AML subtypes, with the possible exception of CD34 [62]. Specifically, CD34 is
detected on undifferentiated hematopoietic progenitors and can also be found on the
blasts of patients with either AML or ALL. There is evidence that patients with AML whose
blasts strongly express CD34 have an inferior outcome due to chemotherapy-resistant
leukemia [63]
Historically, AML blasts have been studied through the lens of distinct
chromosomal rearrangements and translocations that appear to drive the oncogenicity of
particular subtypes of leukemia [64]. The different translocations initially observed in
leukemias were generally found stably within the entirety of the malignant clonal patient
cell population, thus it was thought that these molecular lesions occur as early hits during
disease development and have a direct causal role in disease progression and pathogenesis
[58;

65].

Thus, several of these recurrent chromosome abnormalities are now included in

the 2008 revision of the World Health Organization (WHO) classification scheme of AML.
For example, translocation t(15;17)(q22;q12) generates the PML–RARa fusion gene and
is exclusively associated with acute promyelocytic leukemia (APL, AML–M3) [66].
Cytogenetic analysis of AML patient blasts has demonstrated clinical efficacy in subsets of
patients with clonal lesions that have proven chemotherapeutic agents [67; 68]. However, it
is now understood that genetic mutations such as single nucleotide substitutions and
small tandem duplications account for more than 70% of all driver molecular lesions in
AML [60].
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Genetic mutations typically co-occur with chromosomal rearrangements, but also
arise independently of any karyotypic abnormality. Importantly, almost half of all AML
patients have a cytogenetically normal karyotype (CN-AML) and has been historically
classified as intermediate risk according to the European Leukemia Network (ELN)
guidelines. Interestingly, although patients typically harbored more than 1 driver genetic
mutation, particular sets of these genetic features have been able to cluster AML patients
into groups with significant prognostic relevance [69]. Furthermore, studies suggest that
distinct genetic abnormalities have a likelihood of occurring between early and late disease
development [70; 71]. Therefore, AML blast clones have the potential of evolving over time,
further acquiring genetic lesions and generating multiple competing clones at any time
within the same patient (Figure 1.4). Consequently, this phenomenon results in negative
outcomes such as lower overall survival, chemotherapeutic resistance and disease relapse.
Thus, while most AML patients without cytogenic abnormalities have been historically
classified as intermediate risk, most patients indeed harbor genetic mutations that could
confer aggressive oncogenic cellular programs. Therefore, the current gold-standard of
care for AML patients involves performing testing for recurrent mutations in genes
associated with AML, in conjunction with morphological and cytogenic analysis, to
comprehensively diagnose the patient disease state and create a personalized treatment
model.
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Figure 1.4 – AML Heterogeneity.
Schematic representing how founder
mutations in AML-associated genes lead
to the establishment of a preleukemic
hemopoietic stem cell population that
upon incidence of secondary driver
mutations develop into leukemia. The
additional accumulation of multiple
tertiary mutations results in the patientpatient molecular heterogeneity. Intrinsic
to the AML population. Hematologic
progenitor cells are denoted as such
HSC/MPP/CMP/GMAP (Adapted from
Brumatti et al. 2017)

AML-associated genes. Comprehensive mutational analysis of AML patient cohorts
has revealed sets of genes that have recurrent genetic mutations (Figure 1.5).
Interestingly, mutated genes span a range of categories such as hyperactivated growth
signaling,

hematopoietic

transcription

factors,

chromatin

modifiers,

DNA

methyltransferases and RNA splicing factors [60]. Particular genetic mutations identified
within AML-associated genes express higher penetrance than other commonly studied
cytogenic abnormalities and chromosomal rearrangements. Furthermore, these genetic
mutations exhibit complex patterns of cooperation and mutual exclusivity between
themselves, suggestive of the need for distinct additive effects that are balanced to
promote the oncogenicity of AML blasts.

19

Introduction

Figure 1.5 – Frequency of mutational events in AML-Associated genes that are
cumulatively the most frequent across two independent patient cohorts of de novo AML –
BeatAML (n = 531) and TCGA-LAML (n = 200 patients) (Data obtained from Tyner et al
2018 Figure 1A) Of note, although only one patient with a mutation in SRSF2 was reported
in the TCGA-AML publication, retrospectively mutational analysis of RNA- seq data
identified SRSF2 hotspot mutations in each of these 19 patients (11% of the patients with
AML) [72]. This retrospective finding is consistent with the frequency of mutations in
SRSF2 identified across patients of the BeatAML cohort.

The gene FLT3 (Fms Related Receptor Tyrosine kinase 3, also known as CD135) is
the most commonly mutated gene across the AML population, with around 33% of
patients harboring an internal tandem duplication (ITD) that is not identifiable through
traditional cytogenetic analysis [73]. The FLT3-ITDs are nucleotide duplications whose
length can vary from 3 to more than 400 base pairs generally recurring between exons 14
and 15, resulting in the insertion of repeated amino acid sequences within the juxta-
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membrane domain of the FLT3 protein. The encoded FLT3 transmembrane protein is
selectively expressed in CD34+ hematopoietic stem cells [74] and its coordinated signaling
is important for proper development of normal hematopoietic stem cell self-renewal and
differentiation. Crystallography studies showed that FLT3 juxta-membrane domain
makes contact with the activation loop to maintain the protein in an auto-inhibited
monomeric state [75]. The kinase activity of FLT3 is normally stimulated upon ligand
binding, which promotes the dimerization and the concomitant juxtaposition of the
cytoplasmic domain of the FLT3 receptor and facilitates trans-phosphorylation of its
tyrosine residues [73; 76]. Thus, the ITDs in the FLT3 juxta-membrane domain as well as
mutations in the activation loop promotes hypersensitive receptor dimerization as well as
ligand-independent trans-autophosphorylation. Consequently, the constitutive activation
of the FLT3 signaling pathway results in cytokine-independent proliferation and blocking
myeloid differentiation of hematopoietic progenitors [77]. Consistently, increased allelic
ratio of the FLT3-ITD mutation is known to correlate with poor prognosis. [78]
The second largest AML disease subgroup, accounting for slightly less than 30% of
the population, is defined by mutations in the gene NPM1 (Nucleophosmin 1). The gene
encodes a molecular chaperone phosphoprotein that oligomerizes to form a pentamer, and
sometimes a decamer, that shuttles between nuclei and cytoplasm, with pleiotropic
functions including ribosomal biogenesis [79], centrosome duplication [80], and regulation
of p53 [81]. Mutations, typically insertions, in the NPM1 gene are typically concentrated in
exon 12 and involve a frameshift (W288fs) which results in the cytoplasmic sequestration
of a truncated protein. Interestingly, mice expressing the Npm1-W288fs mutation develop
myeloproliferative neoplasms but not overt leukemia [82], suggesting that it may require
additional mutations to promote leukemic development. Concordantly, many patients
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carrying NPM1 mutations also carry the FLT3-ITD mutation as well as mutations in one
or more DNA methylation genes such as DNMT3A [64]. NPM1 mutations in the absence of
FLT3-ITD or other mutations are associated with good prognostic outcomes.
Of note, mutations in NPM1 were significantly exclusive of point mutations that
occur in hematopoietic transcription factor RUNX1 [69;

83].

The RUNX family

transcription factor 1 (RUNX1) is essential for the function of hematopoietic stem cells and
is the most frequent target for chromosomal translocations in leukemia [83;

84].

Loss of

function point mutations are mostly clustered in the Runt domain at arginine residues
R107, R162, and R201 and aspartate residue D198. In particular, biallelic mutations in
RUNX1 have been observed in AML-M0 patients, indicating a complete lack of RUNX1
function in their leukemic cells [85]. Therefore, leukemogenesis in RUNX1 mutated
patients is thought to promote growth advantage to the hematopoietic progenitor cells
with differentiation defects that result from mutations in other genes [83]. Intriguingly,
mutations in RUNX1 significantly co-occurred with mutations in DNMT3A, chromatin
factors and splicing factors [69]
Around 20% of AML patients harbor point mutations in DNA methyltransferase 3
Alpha (DNMT3A), which has been recently described as a recurrent founder mutation [69].
Further analyses found mutations in genes that encode other epigenetic modifiers such as
ASXL1 and TET2. In particular, DNMT3A catalyzes the addition of a methyl groups to
concentrated clusters of cytosine residues in DNA regions upstream of genes, thereby
reducing the expression of the downstream gene [86]. Aberrant DNA methylation is widely
accepted to contribute to the pathogenesis of AML and of cancer overall. Of note, clonal
patterns with initial mutations in these epigenetic factors may potentially promote the
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occurrence of myelodysplastic syndrome (MDS), a pre-malignant disease that also affects
myeloid cells and is known to progress to AML
Additional epigenetic avenues such as chromatin remodeling are disrupted in
AML. Partial tandem duplications (PTDs) in Lysine Methyltransferase 2A (KMT2A also
known as Mixed Lineage Leukemia 1 or MLL1). The KMT2A protein SET domain is
responsible for histone H3 lysine 4 (H3K4) methylation and is implicated in regulating
the transcription of specific target genes, including the Hox gene cluster which are
involved in hematopoiesis [87]. Loss of function point mutations in other chromatin factors
such as EZH2 particularly downregulate the catalytic activity of the SET domain which is
responsible of deposition of di- and trimethylation on lysine 27 of histone H3
(H3K27me2/3) [88]. Loss of EZH2 protein induces resistance to multiple drugs in AML,
presumably through derepressing the HOX gene cluster [89]. Overall, mutations within
hematopoietic transcription factors, signal transduction receptors, epigenetic regulators
and chromatin modifiers broadly dysregulate networks of gene expression, and largerscale studies of AML population have sought to determine how gene expression profiles
confer oncogenic capacity of the malignant blasts
Around 18%-20% of AML patients harbor mutations in genes encoding RNA
splicing factors U2AF1, SRSF2, SF3B1, and ZRSR2, which are all involved in 3’ splice site
selection (Figure 1.6) [21;

90].

Importantly, mutations in these splicing factors are

mutually exclusive, suggesting that two mutations in distinct splice factors is not viable for
the cell. Mutations in splice factors in particular showed slight patterns of co-occurrence
with mutations in chromatin factors as well as RUNX1 and other myeloid transcription
factors, but were significantly exclusive of mutations in DNMT3A and NPM1 [91]. The SRprotein SRSF2 – previously known as SC35 –binds to exonic splicing enhancers and is

23

Introduction
required for the ATP-dependent interactions between U1 and U2 snRNP. Specifically,
hotspot mutations in SRSF2 typically convert residue proline 95 (P95) to a histidine (H),
leucine (L), or arginine (R) which alters the RNA-binding specificity of the RNA-binding
domain and drives preferential recognition of cassette exons containing C-rich versus Grich sequences in exon exonic splicing enhancers (Figure 1.6A) [92]. Inducible Mx1-Cre
Srsf2P95H/WT knock-in mice displayed hallmarks of myeloid disorders such as MDS [92].
Similarly, the SR-protein U2AF1 also harbors hotspot mutations, which fall in the
Zn knuckles and typically affect either residues S34/S35 or R156/Q157 and are also
thought to alter preferential binding to the 3’ ss (Figure 1.6B). U2 auxiliary factor 1
protein – also known as U2AF35 – is 65 kaDa subunit non-snRNP protein required for
the binding of U2 snRNP to the pre-mRNA branch site. Recombinant mice conditionally
expressing U2AF1(S34F) had impaired hematopoiesis but did not develop leukemia,
suggestive of the need for cooperative mutations, particularly in hematopoietic
transcription factors [93]. Additionally, mutations in spliceosome machinery, usually
within U2AF1, have been found to increase the occurrence of MDS with high probability
of development into AML [94]
Mutations in splicing factors SF3B1 and ZRSR2 are significantly less frequent in
AML (Figure 1.6C-D) [69,95]. The SF3B1 protein – previously known as SAP155 –is the
largest component of a 450-kDa hetero-heptameric SF3B complex, a subunit of 17S U2
snRNP and the analogous minor spliceosomal U12 snRNP [96]. The splicing factor 3b/3a
complex binds pre-mRNA upstream and downstream of the intron's branch point
sequence and recruits the U2 snRNP to the pre-mRNA [97]. In particular, point mutations
in SF3B1 mostly occur at lysine residue 700 (K700), which falls within the HEAT domain
of SF3B1 [90]. Mutations in this residue disrupt the interaction with another auxiliary
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splicing factor, SUGP1, and interfere with the interactions that support the scaffolding for
the U2 snRNP and other SF3B subunits, resulting in widespread changes in alternative
splicing [98]. Similarly, mutations in ZRSR2, which are loss-of-function missense,
frameshifts and nonsense mutations that occur across the protein and are also thought to
interfere with protein-protein interactions with other components of the spliceosome [99].
ZRSR2 is known to interact with the U2AF1/2 complex and also regulate the splicing of
introns U12-dependent minor spliceosome [100; 101].
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Figure 1.6 – RNA Splicing Factor Mutations in AML (A) SRSF2 hotpot mutations
P95H/L/R alters the RNA-binding domain causing preference for an exonic enhancer with
CCNG motif over a GGNG motif. (B) U2AF1 hotspot mutations at residue S34 and Q157
create distinct preference for cysteines and guanines at the 3’ splice site respectively (C)
Mutations in SF3B1 interfere with the spliceosome protein scaffolding and impede branch
point recognition which may lead to cryptic splice site usage (D) Mutations in ZRSR2 also
interfere with protein-protein interactions between spliceosome machinery and may
induce aberrant retention of U12-type introns. (Adapted from Dvinge et al. 2016 Figure 3)
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Transcriptomic Profiling of AML Patients. A handful of researchers have previously
sought to define dysregulated gene expression and splice site choices associated with the
leukemogenesis of AML blasts. Historically, exploratory studies of the AML transcriptome
were limited to Affymetrix microarray gene chips [102; 103; 104; 105] and exon junction probe
sets [106; 107] to quantify changes in gene expression and alternative splicing respectively.
For example, microarray studies have identified overexpression of the HOX gene cluster
in particular within AML patients with NPM1 mutations as well as with +8/8q karyotype.
More recently, studies utilizing high-throughput short-read RNA sequencing have sought
to further identify prognostic signatures in gene expression and alternative splicing
variations. For example, unsupervised clustering analysis of RNA-seq expression data
from at least one large AML cohort revealed correlations with overall survival, as well as
with particular morphologically defined subgroups of AML and genetic mutations in AMLassociated genes [64]
The overexpression of genes pertaining to the HOX gene cluster has also been
found implicated in leukemogenesis, AML disease progression and overall poor prognosis
[108;

109; 110].

Interestingly, one study in pediatric AML found it possible to distinguish

patients with NPM1 mutations from those with 11q23/MLL translocations based on
different patterns of HOX gene expression [111]. Additionally, one study performed in
recombinant Mx1-cre mice linked the expression of several hematopoietic regulators
including upregulation Hoxb2 and downregulation genes such as Gata1 and Gata2 to the
conditional expression of Srsf2P95H [92]. Alternative pre-mRNA splicing promotes
oncogenicity via de novo synthesis of aberrant splice isoforms as well as through
disruption of normal ratios of splice isoforms. For example, it was demonstrated in mouse
models that alternative splicing of Hoxa9 translates to a truncated version of the protein
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(Hoxa9T) which binds strongly to CREB-binding protein and activates transcription of
proto-oncogenes [112].
Transcriptomic perturbations to only some of the AML-associated genes have been
previously described (See Table 2.1). FLT3 is one of the most highly mis-spliced genes in
AML with aberrant splicing of the transcript primarily altering an extracellular region of
this receptor [113]. The FLT3 pathway frequently hyperactivated in AML controls many
downstream target genes, including apoptotic regulator BIRC5. Splice variant ratios of the
BIRC5 gene, which encodes the Survivin inhibitor of apoptosis, are significantly associated
with risk of refractory disease and poor survival outcomes in both children and adults [114;
115].

The gene RUNX1 also frequently mutated in AML encodes a minor splice isoform

often seen at higher levels in AML patients that lacks the transactivation domain and binds
DNA with higher affinity than the full-length isoform thereby acting in a dominant
negative fashion [116]. Furthermore, the handful of studies that have sought to uncover
differential splicing changes that are common across AML patients usually compare an
entire group of patients to non-malignant cells [117;118;106]. However, this particular
strategy overlooks the intrinsic heterogeneity of AML given that the assumption with this
model is that every AML patient has the same molecular background, and this has been
demonstrated to be untrue. The aforementioned splicing studies also use algorithms that
fail to capture de novo and complex splicing variations, thus overlooking important
changes that likely arise in the cancer transcriptome.
It is evident that analysis of mutational status level alone underestimates the
molecular heterogeneity of AML blasts and overlooks important variations at the level of
pre-mRNA processing and gene expression. Importantly, variations in pre-mRNA splicing
within AML-associated genes themselves are capable of eliciting loss-of function or change
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of function effects. However, transcriptome-wide splicing quantification analyses have
also only been done centered around a genetic mutation in a splicing factor or a particular
AML-associated gene. Thus, an alternative question, which has not been addressed by
previous studies, is whether splicing variations across AML patients serve as an
independent mechanism to somatic mutations by which the function of AML-associated
genes may be altered. In the work performed for this dissertation, I investigate how premRNA splicing variations functionally dysregulate AML-associated genes. The
overarching goals of this dissertation are to expand the repertoire of transcriptomic
variations expressed among the AML population and to explain the mechanisms by which
an mRNA splice variant can phenocopy the effects of genetic mutations within AML
associated genes. In the following chapters, I elaborate on an exploratory analysis
deployed over an in-house cohort of AML patients. The analyses lead to the identification
of alternative splicing patterns that were also observable in a larger and independent AML
cohort with a striking degree of correlation. The occurrence of a handful the most
interesting splicing events was validated experimentally in patient derived AML blasts.
Finally, I expand the landscape of commonly altered genes in AML by identifying
deleterious splicing events within genes not previously linked to the development of this
disease. Taken together the body of work presented in this dissertation underscores that
future studies and clinical pipelines need to account for variations in mRNA splicing to
fully profile the molecular heterogeneity of AML and design personalized therapeutic
strategies.
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Introduction
No previous studies have robustly profiled variations in RNA splicing within genes
that occur with high mutational frequency in AML. As discussed in Chapter 1, splicing
variations may serve as an additional mechanism to somatic mutations by which the
function of these genes may be altered. Specifically, for the studies discussed in the
following chapter, I hypothesized that accounting for variations in splicing would increase
the percentage of AML patients that harbor molecular alterations within a particular AMLassociated gene. To test the above hypothesis, I quantified splicing variability of genes that
have been identified as commonly mutated, truncated, or translocated in AML patients.
The geneset was initially obtained from the analysis of genetic mutations performed as
part of the TCGA-LAML project [64], which was among the first large scale studies to
perform coupled whole genome and exome sequencing analysis in AML to identify
candidate somatic variants that a recurrently associated with AML. An additional study of
AML genomes, the German-Austrian AML study group, which spanned multiple centers,
confirmed the genetic mutations described by the TCGA study for an a priori defined set
of genes [69]. Furthermore, a yet another large study of AML genomes confirmed most of
the previously identified mutations [95] and a retrospective analysis of RNA-seq data of
TCGA-AML highlighted the overlooked increased occurrence of SRSF2 mutations in AML
[72].
For my analysis of splicing variations in AML-associated genes, I compiled a list of
those genes that were found to be commonly mutated in more than 1.5% of AML patients
across the aforementioned studies. The curation resulted in a list of 70 genes of interest
that I focused on for the analyses discussed in the following Chapter. Herein, I analyze
polyA-selected RNA-Seq data from 29 in-house de-identified AML patient samples
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collected by the Penn Stem Cell and Xenograft Core (aka PENN-AML cohort). Samples in
the PENN-AML cohort were isolated by leukapheresis or from peripheral blood
mononuclear cells (PBMCs), and RNA-Seq data was generated from samples with an AML
blast purity of greater than 90% (sample information published in Rivera et al 2021, RNASeq data is available in GSE142514). Thus, samples within the PENN cohort can be
quantitatively compared without concern of confounding factors tied to sample purity.
Specifically, I used the novel MAJIQ computational framework discussed in Section 1.4 to
process the RNA-sequencing files from the PENN-AML patient cohort (Figure 2.1A). By
using the MAJIQ algorithm, the analysis was optimized to detect and quantify complex as
well as novel splicing events, and thus was not limited to previously observed or expected
splicing patterns.
As previously discussed in Chapter 1, the MAJIQ framework outputs a catalogue of
local splicing variations (LSVs) that represent any splicing events, constitutive or variable,
that are quantified transcriptome-wide or for a defined set of genes. Given the context of
my study, I particularly focused on configuring the MAJIQ framework to quantify splicing
events for the aforementioned 70 AML-associated genes (Figure 2.1B, C). The LSVs that
are outputted by MAJIQ represent a highly dimensional dataset with some level of
redundancy. In other words, there are cases where LSVs overlap with one another and
point to the same splicing event but through different angles of the transcript. To resolve
these cases and to reduce the dimensionality of the LSV dataset, I coded a pipeline that
groups overlapping LSVs into splicing modules (Figure 2.1D). Thus, each splicing
module represents either 1 individual LSV, which in turn represents 1 splicing event, or 2
overlapping LSVs that share a particular junction of what is actually the same single
splicing event. If two LSVs formed a splicing module, the most variable junction across all
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the grouped junctions in both LSVs was selected as the junction representative of the
variance for the particular module.
The goal of this study is to quantify splicing variation that underlies patient-topatient heterogeneity; therefore, of interest were the most highly variable splicing modules
quantified within the dataset (Figure 2.1D). Therefore, for each module, the pipeline
calculated the variance in PSI for each junction, which is essentially how much the percent
usage of each junction deviates across the sample cohort. For each splicing module, the
most variable junction within the splicing module was selected as the representative
junction. The splicing module data feature facilitates downstream analyses by focusing on
using only the values that are representative of the underlying biological variation in
question across AML cohorts. Upon identifying a particular splicing module of interest, I
can query the outputted database for the particular underlying LSV and visualize it in the
VOILA visualization engine that is part of the MAJIQ framework. Herein, I provide a
catalogue of the variations in pre-mRNA splicing many of which are novel and have not
been described in previous studies (Table 2.1). Furthermore, I find that AML patients
harbor highly variable splicing events with a striking level of correlation. This finding fits
well with the widely accepted fact that alternative pre-mRNA splicing events are known to
be co-regulated by distinct RBPs.
In my analysis of splicing variations, I also included the BeatAML cohort, a large
multicenter study that performed RNA-seq analysis in 444 AML patients [95]. Importantly,
as I will discuss in detail in the following Chapter, the splicing events that I uncover in the
PENN-AML cohort are also found to behave similarly within the BeatAML cohort.
Additionally, I experimentally validate a handful of splicing events of interest using RNA
isolated from a subset of patients that form part of the PENN-AML cohort. The correlation
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between the experimental results and the MAJIQ-PSI quantifications were particularly
striking and thus serve to highlight the power of the MAJIQ computational framework for
the robust detection of molecular alterations at the level of mRNA splicing within patient
RNA-seq data. Therefore, the results discussed in the following Chapter strongly support
that analysis of mutational status alone underestimates the true percentage of AML
patients exhibiting functional downregulation of a particular gene. Therefore, my study
for the first-time sheds light on dysregulated splicing variations that may be indicative of
particular subsets of AML patients. Through the body of work discussed in this Chapter, I
aim to motivate studies that address the contribution of pre-mRNA splicing variations to
the pathology of AML.

Figure 2.1 – Study design and splicing quantification pipeline (A) Workflow of
transcriptomic analysis from 29 primary AML samples obtained from the Penn Tumor
Bank. (B) List of 70 AML-associated genes targeted in MAJIQ analysis. (C) MAJIQ
pipeline for the analysis of splicing variations of AML-associated genes within PENN-AML
patient RNA-seq data (D) Schematic of splicing module definition using extended pipeline
coded for the purposes of this study.
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Results
Highly variable splicing events within AML-related genes. Splicing modules that
exhibited a variance greater than one standard deviation above the mean variance for all
modules were deemed as the ‘highly-variable’ splicing modules within AML-associated
genes. (Figure 2.1A). The MAJIQ pipeline quantified a total of 506 splicing modules that
were quantifiable in at least 80% of the PENN cohort (at least 24/29 patients). Most of
these splicing events exhibit low variability amongst samples which is expected given the
general need for splicing to be conserved as a consistent step in gene regulation. However,
I identified 40 splicing modules that poses a variance above the calculated threshold cutoff
(Figure 2.2A-B). These 40 highly variable splicing modules implicated 25 of the 70 AMLassociated genes. Multiple splicing modules within the same gene suggests that the
occurrence of multiple distinct avenues of biological regulation. Importantly, gene
expression for these same 70 genes showed overall less variability than splicing, and none
of the genes harboring highly variable splicing modules were amongst those with highly
variable expression. Importantly, splicing variability of all of the 40 highly variable
modules is independent of differences in transcript abundance and cis-acting mutations.
Furthermore, although most of these splicing modules are predicted to have deleterious
effects on the expression of the encoded protein, most of these splicing modules have not
been described in the literature (Table 2.1). The observed variability in splicing that is
independent of gene expression patterns and mutational status across PENN-AML
patients underscores significant differences in the AML transcriptome that are not
captured by standard genetic and gene expression analysis.
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Figure 2.2 –Splicing variability and gene expression heterogeneity of AMLassociated genes across the PENN-AML patient cohort. (A, left) Distribution plots
of 506 splicing modules (x-axis) that were quantified in at least 80% of patients, sorted by
the most variant PSI for each module (y-axis). The red cutoff line identifies modules with
a variance of one SD (105.21) above the mean (54.26). (A, right) The 40 splicing modules
above the threshold in B replotted according to SD of PSI. The most variable module is
indicated in the plot. See Fig. 2 for details. (B) Heatmap showing transcript abundance
values (Left) and PSI (Right) for each of the 40 highly variable modules. Rows are sorted
by module number from rank sorting in panel A, with a list of these 40 modules on the far
right. Where more than one variable module is observed within a gene, these are
differentiated by a number after their gene name. Columns in both heatmaps are
identically ordered and sorted based on PSI of the most variable module (EZH2 exon
11/12). Patients were then assigned letters consistent throughout this study. Gray square
within the splicing PSI heatmap indicates an unquantifiable module in a given sample.
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Table 2.1 – Splicing Modules quantified within AML-associated genes across
the PENN-AML patient cohort.
Splicing
Module*

Effect‡

Description

Literature
Reference°

LOF

Skipping of exon 11 and exon 12 leads
to frameshift and PTC in the upstream
exon.

No study found

FBXW7

COF

Inclusion of regions in 5'UTR. A
significant difference in translational
efficiency among these 5′-UTRs
variants has been observed by in vivo
Luciferase reporter assay and Western
blot.

Liu et al. 2012

U2AF1.1

LOF

Splicing together of mutually exclusive
exons 3 and exon3b leads to PTC

Chang et l 2019

PTPN11

LOF

Inclusion of cryptic exon

No study found

DNMT3A

COF

Alternative first exon and promoter
between exon 6 and exon 7. DNMT3Ashort, but not DNTM3A-long, induced
EMT, which is a primary characteristic
of tumor-initiating cells. The DNMT3A
long/short isoforms display differential
localization along the mouse ES cell
genome.

Manzo et al. 2017

BRAF.1

LOF

Alternative last exon with different
3'UTR regions and lengths that are
expected to bind different microRNAs

Marranci et al. 2015

CSF3R

LOF

Inclusion of cryptic region expected to
cause frameshift. Truncated transcripts
for this gene have been found to be
increased in some patients with MDS/
AML.

Lawrence et al. 2018

BCOR.1

COF

Alternative 3' ss in exon 8 controls
inclusion of around 34 amino acids
with three consecutive serine residues.

No study found

GATA2.1

COF

Alternative 5' UTR regions.

No study found

EZH2.1
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STAG2.1

COF

Alternative 5' UTR regions.

No study found

TET2.1

LOF

Inclusion of cryptic exon 2b between
exons 2 and 3 expected to reduce
protein expression.

No study found

ABL1

COF

Alternative first exon.

No study found

STAG2.2

COF

Multiple alternative 5' UTR regions
including alternative first exon. Linked
with STAG2.1.

No study found

COF

Skipping of exon 5 which is in-frame
and removes 17 amino acids and may
affect BCL6-binding domain. Splicing
bypassing exon 5 and/or alternative
splice acceptor usage at exon 8 results
in the previously identified BCOR
isoforms. Only isoforms a and b
contain sequences required for the
interaction with the transcriptional
regulator AF9

BCOR.2

Srinivasan et al.
2003
Kim et al. 2015

EZH2.2

LOF

Cryptic poison exon 9b between exon 9
and exon 10 with a high degree of
conservation.

Kim et al. 2015

BCORL1

LOF

Multi-exon skipping leads to
frameshift

No study found

FLT3.1

LOF

Cryptic exon 4b between exon 4 and 5
expected causes a frameshift leading to
PTC in exon 5

No study found

ETV6

Unknown

Complex cryptic exon inclusion
between exon 3, exon 4, and exon 5
with noticeable conservation of select
intronic regions.

No study found

EZH2.3

LOF

Cryptic Poison exon 3b between exon 3
and exon 4 with a high degree of
conservation.

No study found

FLT3.2

LOF

Inclusion of cryptic exon 17b between
exons 17 and 18 inserts a PTC.

No study found
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ASXL1.1

COF

Complex last exon between exons 4
and exon 5 representative of
long/short isoform switching.

No study found

SMC1A

COF

Multiexon skipping expected to remain
in-frame and change function of
translated peptide

No study found

ZRSR2.1

COF

Alternative last exon representative of
a switch to a short isoform.

No study found

BRAF.2

COF

Linked with BRAF.1 splicing module

No study found

TET2.2

Unknown

Linked with TET2.1 splicing module

No study found

ZRSR2.2

LOF

Skipping of exon 9 which leads to a
frameshift in the upstream exon

No study found

U2AF1.2

COF

Skipping of exon 5 which is in frame
and removes 33 amino acids

No study found

BRAF.3

LOF

Inclusion of cryptic exon causes a
frameshift PTC expected to result in
unproductive transcript.

No study found

NOTCH1

Unknown

Complex first cryptic exon within long
intron with noticeable conservation
regions

No study found.

EZH2.4

LOF

Linked with EZH2.3 splicing module

No study found.

KIT

Unknown

Inclusion of cryptic exon 20b between
exon 20 and exon 21

No study found

TBL1XR1

Unknown

Complex first exon within long intron
with multiple conserved regions.

No study found

TET2.3

LOF

Skipping of exon 6 which leads to a
frameshift that induces a PTC

No study found.

JAK2

LOF

Inclusion of cryptic exon 16b between
exon 16 and 17 which leads to
frameshift that creates a PTC

No study found.

ASXL1.2

COF

Skipping of exon 8 in frame and
removes part of the ASXH domain

No study found.

RUNX1.1

COF

Skipping off exon 2 removes 13 amino
acid sequence

No study found.
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MYD88

RUNX1.2

COF

COF

Skipping of exon 2 removes N-terminal
of the peptide and exerts a dominantnegative effect on LPS-induced, TLR4mediated signaling pathways and
inhibits inflammatory cytokine
production.
Complex last exon representative of
long/short isoform switching.
Alternative and premature C-terminus.
Runx1 exon 6–related alternative
splicing isoforms differentially regulate
hematopoiesis in mice.

Janssens et al 2002
Lesly & Alper 2013

Tanaka et al. 1995

* Splicing modules are sorted by decreasing variance. Red refers to the 23 highly
correlated splicing modules and clustering association discussed in Figure 2.4
‡ Effects of splicing modules are predicted to be loss-of-function (LOF) or change-of-function
(COF) through manual interpretation and literature reference

º Reference studies found elucidating the particular splicing module or a similar event
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Splicing co-regulation pattern across AML cohorts. To determine if the splicing
variability that I have observed is a unique feature of the PENN-AML dataset, or
representative of a pattern within AML, I next queried these 40 highly variable splicing
modules within independent sample cohorts, specifically the large and publicly available
BeatAML patient cohort [95] as well as a cohort of healthy myeloid cells [119]. For this, I
analyzed data from ~440 AML patient samples previously published as part of the BEATAML project. Overall, I found that splicing of the AML-associated genes is generally more
variable in both the PENN and BEAT-AML cohorts than is observed in normal CD34+
cells (Figure 2.3A). Moreover, at least 30 of the 40 modules that exhibited a variance of
greater than 160 in the PENN cohort, also had a variance above this threshold in the
BEAT-AML samples (Figure 2.3B). By contrast, although there is some intrinsic
variability in the same splicing modules in CD34+ cells from 17 healthy donors, my
analysis revealed much less variation. Therefore, the highly variable splicing events I
detect in our in-house AML cohort population is reflective of the AML population at large.
Having found this signature of pre-mRNA splicing variations in the independent
cohort of AML patients, I next queried the data for particularly interesting correlations.
Alternative splicing is a tightly co-regulated process, where one RBP can regulate multiple
splicing events. Thus, I reasoned that multiple splicing variations maybe altered in a
coordinated fashion within the same AML patient. To explore this possibility, I generated
a pairwise matrix of Spearman rank correlations of all the 40 highly variable splicing
modules. To identify co-regulated splicing modules in the matrix, I applied a hierarchical
clustering method to reorder the splicing modules features by their distinct distance.
Indeed, the pairwise-correlation clustering analysis revealed that 23 of these splicing
modules (including EZH2.1) show a high degree of correlation between one another in
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both the PENN and BEAT-AML cohorts, suggesting that these events are co-regulated
with one another (Figure 2.4A). Importantly, this cluster of co-regulation between
splicing modules is not observed in the normal CD34+ cells. This means that although I
found significantly lower yet intrinsic variability present in healthy myeloid cells, the coregulated aspect of these splicing modules is limited to AML patients. Therefore, the coregulated pattern that I observe in AML patients may be arising from some unidentified
source of oncogenic dysregulation of alternative splicing.
The co-regulatory pattern observed in the data described in Figure 2.3 is indicative
of the presence of subclusters of AML patients with abnormal, yet coordinated, pattern of
alternative RNA splicing. Followingly, I performed a pairwise comparison of patient
samples using only the information from the MAJIQ-PSI quantification of the 40 highly
variable splicing modules described above. Indeed, hierarchical clustering of the patient
similarity matrix reveals two visually distinct clusters of patients in the large BEAT-AML
cohort (Figure 2.4B). The sample size of both the PENN-AML and CD34 datasets is
inadequate for patient-patient clustering analysis. However, I can observe in the PENNAML heatmap that there are at least 4 samples that deviate from the rest of the cohort
(Figure 2.4C). Additionally, as expected, there was no visual indication of uncorrelated
samples in the CD34+ dataset. Moreover, the subset of the overall AML patient samples
that had increased skipping of EZH2 exon 11 and 12 (PSI > 25%) significantly overlapped
with the smaller of the two distinct cluster patients (Figure 2.4D).
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Figure 2.3 –Highly variable splicing variations are observed in additional AML
cohort. (A) Variance of PSI for the 40 highly variable splicing modules quantified in the
PENN cohort from Fig. 1, plotted also for that observed in 444 samples from the Beat AML
study or 17 healthy CD34+ cell samples from Leucegene publicly available data. The
orange dashed line indicates the threshold variability from Figure. 2.2. (B) Heatmap of
the variance in PSI observed in the Beat AML cohort and normal CD34+ control cells of
the 40 most variable modules from the PENN cohort. Modules are named as in Figure 2.4.
Colors of module names are based on presence in black or gray clusters in Figure 2.4A.
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Figure 2.4 – Co-regulation of splicing variations in AML-associated genes. (A)
Spearman correlation matrix showing pairwise comparison between each of the variable
modules with all others shown as a heatmap. Hierarchical clustering revealed 23 highly
correlated splicing modules (red box & black bar, names listed on left). Hierarchical
clustering was done based on the PENN (left) data and the same ordering revealed strong
clustering and correlation in the Beat AML data (Middle) but not in the CD34+ cells
(Right). (B) Clustering of BEAT-AML patient-to-patient pairwise comparison. Spearman
correlation was used to generate the patient similarity matrix (C) Patient pairwise
comparison and clustering of PENN-AML (left) and CD34 normal donors(right).

Splicing variations in EZH2 disrupt functional protein expression. The goal of
this dissertation work is to understand how splicing variability contributes to protein
expression and function in patients. Thus, I initially focused on the gene EZH2 because it
contains the most highly variable splicing module and is expected to cause a frameshift
that disrupts translation of full-length protein (Figure 2.5). The EZH2 gene encodes the
catalytic component of polycomb-repressive-complex-2 (PRC2) that confers di- and
trimethylation on lysine 27 of histone H3 (H3K27me2/3) [88]. Specifically, skipping of
exon 11 and/or 12 in the EZH2 gene (Fig. 2A, splicing module 1) results in either case in a
premature termination codon (PTC) prior to the catalytic SET domain. Skipping of these
exons is not observed in two leukemia-related cell lines, MV411 and HL-60, and only
minimally in normal CD34+ cells, but varies from 99% (e.g., patient CC) to 0% (patient A)
in the PENN cohort (Figure 2.5C). This complex exon skipping event in EZH2 has not
previously been described, despite its prevalence in the PENN-AML and BEAT-AML data,
presumably because unlike the analysis done here, most splicing quantification methods
focus on previously annotated and simple binary splicing choices and exclude events with
more than two outcomes. Additionally, I detect a second splicing module in EZH2 that
also introduces a PTC, in this case through inclusion of variable exon 9b. Inclusion of
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EZH2 exon 9b has previously been observed in some AML and MDS patients and has been
shown to induce nonsense-mediated decay (NMD) which in turn leads to loss of protein
expression and a corresponding reduction in H3K27me3 levels [92]. Consistently, I observe
over 40% inclusion in exon 9b in six of the PENN patients (Figure. 2.5C bottom, patients
M, P, R-T, V). However, there is no correlation between inclusion of exon 9b and skipping
of exons 11/12 in EZH2. Thus, both of these splicing modules within EZH2 represent
alternative avenues through which this gene may be functionally downregulated in AML
blasts.
Importantly, radiolabeled RT-PCR performed by Michael J. Mallory of the Lynch
Lab validated the occurrence of EZH2 exons 11/12 skipping in several of our AML patient
cells and we observe the predicted decrease in EZH2 protein in these same samples
relative to patients that exhibit little-to-no exon 11/12 skipping (Figure 2.6A). Although
high EZH2 protein in MV411 relative to patients corresponds to high EZH2 RPKM, I am
still able to observe a 10-fold decrease in EZH2 protein in patients with high exon 11/12
skipping (AA and CC) relative to AML patients with high inclusion (N and W).
Heterozygous loss-of-function (LOF) somatic mutations in EZH2 have been described in
AML but are only observed in a small percentage of patients. Consistently, I observe that
4 of our 29 patients (14%) harbor a somatic mutation in EZH2 (Figure 2.5D). By
contrast, I observe 8 additional patients (28%) for which greater than 50% of their EZH2
transcripts fail to encode full-length protein due to skipping of exon 11/12 and/or inclusion
of exon 9b (patients M, R-T, V, AA-CC). Therefore, taking splicing patterns into account
in the transcriptomic analysis triples the percentage of EZH2-deficient patients (14% to
42%), consistent with the notion that splicing variation is an underappreciated contributor
to protein dysregulation in AML.
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Figure 2.5 – Splicing, expression, and mutational analysis of EZH2 across the
PENN-AML patient cohort. (A) Schematic diagram of EZH2 protein domain structure
and (B) the corresponding exon-junction connectivity of the EZH2 gene and with
highlighting of the two most variable splicing modules in EZH2. Also indicated are known
AML- related cis mutations in EZH2 found in the PENN cohort (asterisk indicates
nonsense mutations) and induced premature stop codons (PTC, red). (C, top) PSI values
for exon 11 and 12 skipping and (C, bottom) PSI values for exon 9b inclusion in patients,
cell lines (HL-60 and MV411), and CD34+ normal cells. NQ for patient B indicates this
LSV was not quantifiable in this patient. Red squares indicate patients with EZH2 splicing
variations at PSI levels that are expected to functionally downregulate the resulting
protein (D) Gene expression (Top) and mutational status (Bottom) of EZH2 as well as two
known regulatory proteins SRSF2 and U2AF1 in the samples corresponding to B and C
above.

48

II – Alternative splicing functionally disrupts genes associated with AML

Figure 2.6 – Experimental Validation
of splicing variations in AML patient
blasts. Radiolabeled RT-PCR validations
of (A) skipping of EZH2 exons 11/12 and
inclusion of exon 9b, (B) inclusion of
ZRSR2 exon 3b and skipping of exon 9
within selected patients, and (C) of U2AF1
exon 3 to 3b splicing. Diagrams in the
upper right corner show splicegraph with
primers targeting exon junctions of
splicing events. The RT-PCR expected
product schematic and nucleotide size are
shown to the right of gel image. Colorcoded bar plots below each radiolabeled
RT-PCR
panel
shows
MAJIQ-PSI
estimates. (caption continued in next
page)
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(Figure 2.6 continued). The gel images below radiolabeled RT-PCR panels show western
blot analyses. Below each blot are plots of log2(RPKM) transcript expression levels
pertaining to each particular gene panel. (radiolabeled RT-PCR and western blots were
performed by Michael J. Mallory from the Lynch Lab).
Previous studies have shown that one driver of EZH2 exon 9b inclusion is mutation
of the splicing regulatory protein SRSF2. Specifically, mutation of SRSF2 proline 95 (P95)
to histidine, lysine or arginine alters the mRNA binding specificity of this splicing factor,
resulting in its binding to sequences within EZH2 exon 9b to promote exon 9b inclusion
[92]. Using the RNA-Seq short-read data, I determined that, of the six patients in the PENN
cohort that exhibit highest inclusion of EZH2 exon 9b, two carry the P95H mutation in
SRSF2, while a third has the P95R mutation (Figure 2.5D). A second mutation that has
been shown to correlate with high inclusion of EZH2 exon 9b in MDS is a S34F mutation
in the core splicing factor U2AF1 [120]. I detect this mutation in patient C, which has low
inclusion of exon 9b, while mutation in the neighboring residue in U2AF1(R35L) co-exists
with high exon 9b inclusion in patient R. The U2AF1 R35L mutation has been detected in
AML but has not previously been shown to drive inclusion of EZH2 exon 9b. Notably, at
least one instance of high inclusion of EZH2 exon 9b lacks known mutations in SRSF2 or
U2AF1 (patient T) while another patient (CC) has the SRSF2 P95H mutation but low
inclusion of exon 9b, suggesting other yet-unidentified drivers of this splicing event.
Moreover, no mutations in SRSF2, U2AF1 or EZH2 correlate with skipping of EZH2 exons
11/12, nor does this splicing event correlate with the gene expression level of EZH2, SRSF2
or U2AF1 (Figure 2.5D). Therefore, none of the features previously described as
correlated with functional EZH2 expression in AML predict the loss of respective protein
observed upon skipping of exons 11 and/or 12.
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Splicing variations in Splicing Factors. Among the genes that contain the coregulated splicing events are those that encode U2AF1 and ZRSR2, both splicing factors
themselves that participate in the recognition and use of 3’ splice sites [121; 100]. The most
highly variable splicing module in U2AF1 involves the inclusion of both exon 3 and 3’
which results in a stop codon in exon 3’ (Figure 2.7A-B). The U2AF1 gene contains
duplicated tandem exons between exon 2 and exon 4. These two duplicated tandem exons
(3a and 3b) are mutually exclusive in splicing and yield two highly similar protein
isoforms, U2AF1a and U2AF1b. They are evolutionary conserved and only differ by seven
amino acids in the final protein products (97.1% identity) [122]. Although radiolabeled RTPCR confirmed the inclusion of both exon 3 and 3’ by, this event represents less than 25%
of the transcripts and thus, not surprisingly, does not correlate with a detectable decrease
in full length U2AF1 protein (Figure 2.6C). I also note the presence of another splicing
module (U2AF1.2, module 28) that involves skipping of exon 5, which is predicted to result
in an in-frame deletion (Figure 2.7A, C). However, I also don’t observe any smaller
U2AF1 protein in the Western blot. Although there is some heterogeneity in the expression
of U2AF1 [var(RPKMU2AF1) = 0.51] across PENN-AML patients, there was no significant
correlation between the splicing of U2AF1 and the RPKM of its own transcripts. The
patients that have higher splicing variability in U2AF1, seem to have increase transcript
expression in terms of RPKM, which may suggest that the patient AML blast is attempting
to compensate for the molecular impact of altered U2AF1 splicing, however, it remains an
open question the particular impact these may have in functional protein abundance, and
thus, I cannot make any predictive statements about the spliceoforms that I find in U2AF1.
By contrast, in the AML patients for which we had protein samples, I do observe a
clear reduction of full-length ZRSR2 protein that correlates with splicing variation

51

II – Alternative splicing functionally disrupts genes associated with AML
(Figure 2.6B, Figure 2.8A-D). Four patients (V, AA, BB and CC) exhibit greater than
25% splicing from exon 3 to an alternative terminal exon 3b, rather than to exon 4 and
beyond to encode the full-length protein (Figure 2.8A top, and 2.8B) The alternative
termination exon 3b is annotated to have its own 3’UTR, so the expression of a smaller
protein isoform is likely. However, I do not observe the presence of a smaller isoform by
Western blot analysis. I also detect near-complete skipping of ZRSR2 exon 9 in one patient
(patient W), which introduces a premature stop codon (Figure 2.6B, 2.8A bottom, and
2.8C). By Western blot, there is slightly less ZRZR2 protein in patient W compared to
patient N, which seems has the highest levels protein of the 4 patients tested. Patients CC
and AA have lower protein expression which is correlated with the inclusion of exon 3b.
Similar to all of the splicing events that I have discussed, the overall transcript expression
for ZRSR2 is uncorrelated with cis-acting splicing variations. Additionally, there slightly
less heterogeneity in the transcript expression of ZRSR2 across the AML patient samples
[var(RPKMZRSR2) = 0.34] compared to U2AF1 and EZH2 [var(RPKMEZH2) = 0.58] (Figure
2.8D). Therefore, the identification of these two splicing events in ZRSR2 uncovers
multiple avenues by which the encoded protein may be functionally downregulated.
Overall, the identification of splicing events within splicing factors themselves that are
part of the co-regulatory cluster generates new questions with regards to how the splicing
modules that I have uncovered are manifested in AML blasts (See Discussion).
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Figure 2.7 – Splicing, expression, and mutational analysis of U2AF1 across the
PENN-AML patient cohort. (A) Schematic diagram of the U2AF1 protein domain
structure and the corresponding exon connectivity in U2AF1 gene with highlighting of
modules 3 and 28 from Figure 1 and 3. (B) PSI values for module 3; exon 2 splicing to
alternate exons 3 or 3b or 4 (top) or 3 to 3b (bottom) in PENN cohort patients, cell lines
(HL-60, MV411) and CD34+ normal cells. (C) PSI values for exon 5 skipping (module 28)
in PENN cohort patients, cell lines (HL-60, MV411) and CD34+ normal cells. (D) Gene
expression (top) and mutational status (bottom) of U2AF1 in the samples corresponding
to panel B and E.
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Figure 2.8 – Splicing, expression, and mutational analysis of ZRSR2 across the
PENN-AML patient cohort. Splicing, expression and mutational analysis of ZRSR2
across the PENN AML patient cohort. (A) Schematic of ZRSR2 protein domain structure,
and exon connectivity in ZRSR2.1, module 23 from Figure 1 and 3. and exon connectivity
in ZRSR2.2 (module 27, exon 9 skipping). (B) PSI values for exon 3 splicing to alternate
exons 3b or 4 in PENN cohort patients, cell lines (HL-60, MV411) and CD34+ normal cells.
(D) PSI values for exon 9 skipping in PENN cohort patients, cell lines (HL-60, MV411)
and CD34+ normal cells. (E) Gene expression (top) and mutational status (bottom) of
ZRSR2 in the samples corresponding to panel B.

54

II – Alternative splicing functionally disrupts genes associated with AML
Splicing Regulatory Elements associated with co-regulated splicing modules.
Motif analysis for the highly variable modules revealed enrichment of a purine-rich
element in the exons and a U-rich element in introns (T-rich in the genomic signature) as
compared to non-variable modules (Figure 2.9A). ZRSR2 does not have a defined
binding motif, but it is possible that the U-rich motif reflects sequences in a 3’ splice site
that confer regulation by ZRSR2. Accordingly, I also determined if expression of known
purine-rich or U-rich binding proteins exhibited any correlation with the splicing of the
highly variable modules. Interestingly, I there was stronger correlation between gene
expression of SRSF1 and most of the 23 co-regulated modules from cluster C1 discussed
in Figure 3 [µcorr(SRSF1, C1) = 0.28] compared to the rest of the uncorrelated 17 modules
[µcorr(SRSF1, C2) = 0.0981] (Figure 2.9B). A similar but weaker trend was also observed for
hnRNP F, but not for any of several other genes that encode proteins that bind purine-rich
(hnRNP H, hnRNP A1, TRA2A, SRSF7) or U- rich (TDP43, TIA1) motifs, or other splicing
regulatory factors that are mutated in some AML patients (U2AF1, SRSF2).
Although SRSF1 was not included as an AML-associated gene, it is known that
poison exon 4 regulates active expression of this particular gene. I was able to find
increased inclusion of SRSF1 poison exon 4 in the patients that exhibit altered splicing of
EZH2, ZRSR2, U2AF1 and the other splicing variations in the co-regulated cluster,
suggesting that this exon could be part of the co-regulatory splicing network that I have
uncovered. The functional downregulation of SRSF1 protein expression via poison exon 4
inclusion could be influencing the splicing of other splicing modules. Michael Mallory
from the Lynch Lab performed shRNA transfection in Mv411 cells and successfully
knocked down SRSF1 protein, however, we did not observe changes in inclusion across
splicing modules within genes of interest (EZH2, BRAF, BCOR or U2AF1). Thus, altered
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splicing and expression of SRSF1 may be a downstream effect of the aforementioned coregulatory feedback loop instead of a global driver of such variations.

Figure 2.9 – Poly-AAG motifs surrounding variable exons suggest mechanisms
of regulation. (A) Motif enrichment analysis of exonic and intronic sequences
encompassed in the high variable splicing modules. (B) Heatmap of correlation between
expression of RBPs known to bind to GA- or U-rich sequences and PSI of highly variable
splicing modules. (C) SRSF1 active gene expression levels across the PENN-AML patient
cohort. SRSF1 active gene expression was calculated by multiplying the gene abundance
values [log2(RPKM)] with the levels of inclusion (PSI) of known poison exon 4.
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Discussion
In sum, the analyses presented in Chapter 2 highlight alternative RNA splicing as
a major contributor to gene dysregulation in AML. In particular, I find that alternative
splicing of EZH2 and ZRSR2 lead to a higher penetrance of loss of function molecular
lesions of these genes in AML than has been previously recognized. While I focused this
study on splicing variations that reduce protein expression and function by either
introducing PTCs or frameshifts, several of the highly variable splicing modules I detect in
the AML patients cause internal in-frame changes to the open reading frame as well as
alter the N-terminus or C-terminus of the encoded protein by including alternative first or
last exons respectively. (Table 2.1). Of note, for over half of the genes that harbor gainor change-of function genetic mutations in AML as well as highly variable splicing
modules, the respective altered splicing is predicted to change the function of the protein
rather than introduce a PTC. This consistency in the impact of molecular alterations within
the same gene via two distinct avenues suggests that these in-frame splicing variations
may also phenocopy genetic mutations as I have observed for the LOF mutations.
However, more work will be required to fully elaborate the functional consequences of
these in-frame splicing variations and compare their effect to genetic mutations in the
same genes (Discussed in Chapter 4).
Questions still exists about the mechanism that drives the observed splicing
variability. The lack of correlation between splicing patterns and the mutation status or
expression of the same gene argues against cis-regulatory effects. By contrast, the fact that
several of the splicing variations exhibit strong co-correlation across the AML population
implies the dysregulation of a common upstream trans-acting factor(s) that controls many
or all of these events. One mechanism I explored was whether altered splicing of U2AF1
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or ZRSR2, both encoding factors involved in 3’ splice site selection, leads to altered
splicing of the co-occurring modules. Similar to the experiments conducted for SRSF1,
shRNA-mediated knockdowns of ZRSR2 or hnRNP F in MV411 cells also had no impact
on splicing of the correlated modules in EZH2, BRAF, BCOR or U2AF1. Thus, I was unable
to confirm this prediction as depletion of U2AF1 or ZRSR2 in MV411 cells had no impact
on other splicing events tested. It might be that MV411 cells do not recapitulate the splicing
context of AML cells. Consistently, I observed that MV411 cell lines did not harbor
alternative splice variants when performing the experimental validations of splicing
modules showed in Figures 2.5 to 2.8. This suggests that although the MV411 cell line is
commonly used as a model of AML, these cells have a high fidelity in mRNA splicing which
may not be easily perturbed via transient transfections. Finally, although the experiments
in cell lines were inconclusive, the data does point to potential regulatory factors that may
drive at least some of the variability in splicing within the context of AML.
Another approach I took to identify potential trans-activators of these AML
splicing patterns was to identify motifs that are in common amongst the co-regulated
splicing events. This analysis revealed the enrichment of AAG-repeats and U-rich motifs
in the exons and introns, respectively, of regulated modules. The presence of AAG-repeats,
in particular, is of interest as I also observed a strong correlation between splicing module
variability and expression of SRSF1, a protein known to bind purine-rich sequences and
to promote metastasis (Refer to Chapter 1). Again, while single knock-down of SRSF1 in
MV411 cells did not alter splicing of variable modules in EZH2, ZRSR2 or any other genes
tested, I cannot rule out an underlying cooperative effect as well as cell-type specific
impact on splicing variability within AML cells. I also note that while ZRSR2 has been
implicated in the splicing of U12-type introns, only five of the genes I surveyed have a U12-
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type intron (UPF1, BRAF, MYH11, PTEN, SNC3), and none of these U12 introns were
variable across our dataset. Therefore, while I cannot conclusively define a mechanism for
the co-regulated splicing observed across AML cohorts, my results aim to motivate and
direct future studies of RBPs, to elucidate their potential role in driving the variability in
splicing across AML patients.
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Introduction
The analysis presented in Chapter 2 was focused on 70 genes that have been widely
reported to harbor mutations in sporadic AML; however, splicing mis-regulation could
lead to altered function of genes not previously linked to the occurrence of AML. Many
patients initially exhibiting non-proliferative bone marrow failure syndromes are prone to
the development of AML [123]. Some familial MDS/AML patients harbor mutations in
genes that are known to be also mutated in sporadic AML/MDS such as RUNX, CEBPA
and GATA2 [124;

125; 126]

Recently, an analysis of the largest series of AML/MDS families

assembled to date revealed that several new loci within a set of 20 genes that predispose
families to MDS/AML (Figure 3.1A) [127]. Mutations in these 20 genes have not
previously been described in sporadic cohorts of AML, and no previous study has
specifically focused on querying splicing variations within this set of genes. Therefore, I
hypothesized that some of these genes may exhibit variable splicing capable of disrupting
protein function and phenocopying the deleterious effects of genetic mutation.
In the following body of work, I characterize an undocumented splicing variation
within the gene DHX34 which results in the introduction of a PTC and consequently
downregulates the encoded protein. The DHX34 protein is part of the of DExD/H-type
RNA-dependent family of ATPases/helicases, which include major players in spliceosomal
RNA-RNA rearrangements and RNP remodeling events [96;

128].

Importantly, loss-of-

function mutations in DHX34 were identified in families with early on-set MDS/AML [127].
DHX34 itself is also involved in coordinating NMD activity within the cell, suggesting that
the splicing variation within this gene is part of an undocumented autoregulatory feedback
loop. This finding suggested to me that AML blasts rely on the functional downregulation
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of the NMD pathway to support oncogenic molecular profiles. Therefore, as a follow up
analysis, I also performed an additional query of highly variable splicing events within
genes that encode well-known NMD factors.
The NMD pathway selectively degrades mRNAs harboring PTCs, that if translated
can produce truncated proteins that may result in dominant-negative or deleterious gainof-function effects [129]. The NMD pathway is a widely known quality-control mechanism
that is a highly conserved across eukaryotes [130]. Around 30% of disease-associated
mutations generate PTCs [131]. However, the NMD pathways also regulates the steadystate levels of around 10% of human physiological mRNAs to maintain appropriate levels
of gene expression in response to cellular needs. In mammalian cells, alternative mRNA
splicing activity is tightly coordinated with the selectivity of stop codons targeted for NMD
and the post-transcriptional control of gene expression [132]. More specifically, the
interaction between the spliceosome-deposited exon-junction (EJC) protein complex and
certain NMD factors assembled around the upstream stop codon triggers a series of steps
that ultimately lead to mRNA decay – hence the term nonsense.
The EJC core primarily consists of four proteins: RBM8A (RNA-binding motif 8A,
also known as Y14), MAGOH, eIF4III (eukaryotic initiation factor 4A3), and MLN51
(metastatic lymph node 51. also known as CASC3), all of which participate in NMD [133;
130].

A translating ribosome terminating prematurely at a PTC leaves downstream one or

more EJC complexes, which are not removed from the mRNA and subsequently will
recruit the NMD machinery. During PTC-mediated NMD degradation process, a complex
comprising of the NMD factor proteins Up-frameshift proteins (UPF1, UPF2, UPF3), the
SMG proteins (SMG1, SMG8, SMG9), the translation termination factors eRF1 and eRF3,
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and more recently identified DHX34 are all assembled around the PTC to form the
surveillance complex [134;

135; 136].

Although UPF1, UPF2, UPF3 transiently exist as a

complex, these show different cellular localization [137; 138; 130]. The RNA helicase DHx34
functions as a scaffold protein to promote ATP-dependent molecular transitions so that
SMG1 phosphorylates UPF1 to activate the surveillance complex into a decay-inducing
complex [136].
Interestingly, there is evidence of feedback-dependent regulation of the NMD
process whereby mRNAs coding for most known NMD factors are targeted themselves by
the NMD pathway [139]. In particular, long 3’ UTRs of UPF1, SMG5, and SMG7 mRNAs
have been found to be a main NMD-inducing feature of these mRNAs, suggesting that long
3’ UTRs might be a frequent trigger of NMD. Presumably, dysregulated alternative mRNA
splicing patterns within NMD factor genes are predicted to result in wide-spread changes
to the NMD pathway activity, which can be leveraged by the cancer cell to promote
oncogenicity. Although the NMD pathway activity has been widely studied, overall,
splicing variations within NMD factors genes have been overlooked by previous studies of
AML. Therefore, the analysis I present in the following chapter serves to generate new
questions about the pathology of AML and its relationship to downregulated NMD.
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Results

Splicing mis-regulation in genes associated with familial cases of AML. To test
the hypothesis that familial AML genes may undergo alternative splicing in sporadic AML,
I repeated the MAJIQ and variability analysis I describe above in Chapter 2. Within the
20 genes associated with germline predisposition of AML, the MAJIQ framework coupled
with my custom pipeline identified 186 splicing modules that were quantifiable in at least
80% of the PENN cohort. Indeed, 9 splicing modules in 6 of the 20 genes (Figure 3.1B)
exhibit variability in the PENN-AML cohort above the threshold set in my initial analysis
(see Figure 2.1). Similar to what I observed for the other highly variable splicing events
in Figure 2.1, variability in splicing of these 9 additional modules is independent of gene
expression (Figure 3.1) and is also observed in the BEAT-AML cohort (Figure 3.1D).
The most variable splicing variation was found within the gene FANCA and
represents skipping of exon 41 coupled with alternative 3’ UTR. In particular, FANCA is a
large gene (~80 kilobases) and is acknowledged to produce a significant number of
different splice variants. Thus, the skipping of exon 41 is expected to potentially change
the function of the translated peptide. Of note, although I highlight FANCA as a gene
associated with germline AML, one study found heterozygotes deletions and reduced
expression of FANCA in 4 out of 101 cases of sporadic AML. FANCA is part of the Fanconi
anemia complementation group, and other members of this pathway include FANCD1
which is also BRCA2, a protein that has been extensively studied for its implication in
breast cancer. Lastly, there is crosstalk between the FA pathway and DNA repair pathways,
since FA proteins have been found in complexes with DNA repair proteins such as RPA,
BRCA1 and ATR [140; 141].
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Figure 3.1 – Splicing of genes newly correlated with familial AML is highly
variable across Penn and Beat AML cohorts. (A) Table of familial AML-associated
genes queried for splicing variations with MAJIQ-PSI (B) Distribution plots as in Fig. 1B
of 186 splicing modules (x-axis) from 20 genes linked to familial AML, sorted by the most
variant PSI for each module (y-axis). The red cutoff line identifies modules with a variance
one SD above the mean, while the black line indicates the variability threshold from the
analysis in Figure 2.2. (C) Heatmap showing transcript abundance values (Left) and PSI
(Right) for each of the nine highly variable modules as described in Fig. 1D. (D)
Distribution of PSI values for all nine highly variable modules in the PENN (top, light red)
and Beat AML (middle, dark red) cohorts, plus 17 CD34+ cells from healthy donors
(bottom, blue). Red arrow indicates DHX34 splicing module.
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DHX34 poison exon 12b inclusion is significantly higher in AML. While many
of the other splicing variations that I quantified within this particular set of germline AMLassociated genes may have impact on disease pathology, I find of particular interest the
variable module in the gene encoding the RNA helicase and NMD factor DHX34 (module
7 marked by red arrow in Figure 3.1D, and schematic in Figure 3.2A). Strikingly, over
a third of the Penn and BEAT-AML cohort have greater than 70% inclusion of a 75 bp
cryptic exon carrying an in-frame PTC between canonical exons 12 and 13, which I have
termed as exon 12b (Figure 3.2B-C). In contrast, normal CD34 cells overall show a much
lower inclusion of exon 12b, centered around 50% (PPENNAML = 0.026; PBEATAML < 0.0001)
The helicase core of DHX34 as well as other DEAH box proteins is formed by two
(RecA)-like domains, a winged-helix domain and a helical bundle domain, known as the
Ratchet domain [142] DEAH box proteins also have an accessory C-terminal OB fold
(oligonucleotide-oligosaccharide-binding fold domain), which regulates conformational
changes in the helicase [143]. DHX34 exon 12b is inserted into the OB fold coding sequence
and would presumably remove the CTD tail that is required to activate NMD. Thus, if the
transcript is translated, the resulting truncated protein would be predicted to be nonfunctional in NMD, with the potential of exerting dominant-negative effects. However,
western blots from AML patient blasts that include exon 12b do not reveal the presence of
a C-terminally truncated peptide species. Rather, the inclusion of exon 12b correlates with
a significant loss of full-length DHX34 protein (Figure 3.2D-E). Patients CC and W have
higher DHX34 RPKM than patient N but express less protein, suggesting an attempt to
compensate for the lack of functional protein. Patient AA has significantly less DHX34
RPKM than most other AML patients, suggesting that exon 12b containing transcripts get
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degraded. Patient N has less inclusion of exon 12b and thus has significantly higher protein
expression. Therefore, inclusion of the premature stop codon in exon 12b appears to
destabilize the resulting protein or RNA to decrease expression of active protein, which is
consistent with the function of a poison exon.

Figure 3.2 – Inclusion of DHX34 poison exon 12b is significantly increased
across both PENN-AML and BeatAML cohorts (A) Schematic of DHX34 protein
domain structure and corresponding exon connectivity in the highly variable module. Also
indicated are identified LOF mutations in familial AML. (B) Comparison of distribution
of DHX34 exon 12b inclusion PSI for the three data sets along with the P value for the
differences in distributions. (C) PSI values for DHX34 exon 12b inclusion (Top) and gene
expression (Bottom) in PENN patients, cell lines (HL-60 and MV411), and CD34+ normal
cells. (D) Radiolabeled RT-PCR validation of splicing patterns of DHX34 exon 12b from
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selected patients. (E) Western blot analysis of DHX34 protein expression from selected
patients using an antibody targeting the N terminus of DHX34. (Radiolabeled RT-PCR
and Western blot experiment performed by Michael J. Mallory)

DHX34 poison exon 12b inclusion downregulates RNA decay activity. Given
that the inclusion of DHX34 poison exon 12b abolishes protein expression, it is expected
that this splicing event consequently downregulates NMD activity in the cell. As previously
mentioned, NMD selectively degrades mRNAs harboring PTCs and it has been shown to
target many transcripts that encode full-length proteins. Importantly, no studies have
directly explored target substrates of DHX34 activity. However, one recent study produced
a bona fide set of ~1000 target genes of NMD by combining transcriptome profiling of
knockdown and rescues of distinct NMD factors, in particular UPF1 as well as two SMG
proteins (SMG6/SMG7) [144]. Therefore, I hypothesized that a subset of these welldocumented NMD target genes is expressed at higher abundance upon higher inclusion of
DHX34 poison exon 12b inclusion. To address this question, I filtered for around 700
genes that were readily expressed [log2(RPKM) > 1] across the AML cohorts and
determined 142 significant correlations between the inclusion of DHX34 poison exon 12b
and the gene expression values of the inferred target geneset. (Figure 3.3A). Importantly,
I bootstrapped my analysis by generating a random set of 700 expressed genes and
calculated the mean number of correlations that I could find by random chance a thousand
different times. Strikingly, the set of 700 expressed NMD targets appears to be
significantly enriched for genes positively correlating with expression and inclusion of the
DHX34 poison exon 12b across both the PENN and BEAT-AML cohorts (Figure 3.3B).
In particular, at least four NMD-sensitive genes (CHD2, PARP6, METTL22 and WHAMM)
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that exhibit higher expression in AML patient blasts have previously been linked to
important biological functions and the development of cancer [145; 146;

147; 148]

Figure 3.3 – DHX34 poison exon 12b inclusion correlates with significantly
higher abundance of inferred NMD substrates (A) Pipeline for identifying
potential targets of DHX34 NMD activity. (B) Plot of the correlation between expression
of ∼600 documented NMD target genes and DHX34 exon 12b inclusion in PENN (x-axis)
or Beat AML (y-axis) patients. Each dot represents a single gene. The observed
correlations are in good agreement between the two datasets (Pearson r = 0.3985). Genes
for which correlation was significant in both the PENN and Beat cohorts are labeled in red
(positive correlation) or blue (negative correlation). On the right is a comparison of the
percentage of significantly correlated NMD targets versus the percentage of significantly
correlated genes in a random gene set sampled 1,000 times (P value based on a onesample t test, see Methods). (C) Correlation of the expression of specific genes from B with
inclusion of DHX34 exon 12b from both the PENN (dark red) and Beat (light red) cohorts.
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To more directly test whether the inclusion of exon 12b in DHX34 leads to
deregulation of NMD-target genes, I leveraged the use of a JSL1 (Jurkat Splicing 1) cell
line with fused exon 12b and 13. JSL1 cells are a T-cell leukemia cell line heavily used in
the Lynch Lab as a model system to study the effects of alternative splicing changes [149]
(Figure 3.4A). Dr. Rakesh Chatrikhi of the Lynch Lab engineered the exon fusion using
CRISPR gene editing system. The fusion from exon 12b 5’ss and exon 13 3’ss was chosen
so that the cell is forced to pick the exon 12b 3’ ss when splicing the intron between exon
12 and exon 13. Interestingly, we were unable to obtain any clones that had homozygous
inclusion of the full 75b exon 12b sequence, because it seems like this higher degree of
editing in the cell forces the cell to pick another splice site 50 bp downstream of the original
splice site used for the cryptic exon inclusion (Data not shown). However, we were able to
obtain clones heterozygous for fused exon12b+13 sequence (HET-12B) that resulted in an
increase in the percentage of exon 12b included product by ~20% (Figure 3.4B) similar
to the difference between the AML patients with average inclusion (50%) and high (75%+)
inclusion. Strikingly, this difference in inclusion is sufficient to cause a dramatic decrease
in DHX34 protein (Figure 3.4D). and a marked increase in the transcript abundance of
the NMD gene substrates correlated with DHX34 exon 12b inclusion in the AML patients
(Figure 3.4E). Presumably, downregulation of the NMD pathway results from the
absence of DHX34-mediated coordination of the decay-inducing complex that forms
around the EJC. Therefore, this data strongly suggests that inclusion of DHX34 poison
exon 12b negatively impacts NMD activity within the cell. Furthermore, the increased
abundance of non-functional transcripts presumably interferes with various regulatory
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functions such as binding of RBPs and microRNAs, as well as may potentially allow
translation of truncated proteins that could exert dominant-negative effects.

Figure 3.4 –Forced inclusion of DHX34 exon 12b leads to a reduced DHX34
protein and increased transcript abundance of NMD targets. (A) Schematic of
the mutational strategy to force inclusion of DHX34 exon 12b by CRISPR gene editing to
fuse exons 12b and 13 (B) Genomic PCR analysis of the DHX34 locus in wild-type (WT)
cells compared with those containing heterozygous replacement of the exon 12b to exon
13 region with the fused construct. Cell line was engineered, and clone was selected for by
Dr. Rakesh Chatrikhi of the Lynch Lab who also confirmed accurate repair by sequencing.
(C) Radiolabeled RT-PCR analysis of DHX34 splicing in WT cells compared with the
heterozygous mutant from A. Average quantification of inclusion of exon 12b in final total
DHX34 mRNA is given (n > 3). (D) Western blot of DHX34 protein in WT cells compared
with the heterozygous mutant from A. (E) qPCR of the expression of NMD target genes in
WT cells compared with the heterozygous mutant from A. The average, SD, and P value
(two-tailed t test) are from three independent experiments.
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Splicing variations in NMD factor genes. The loss of functional RNA decay activity
by increased inclusion of DHX34 poison exon 12b is suggestive of the need for
downregulation of NMD to sustain AML disease pathology. Therefore, I hypothesized that
alternative splicing of NMD factors is also dysregulated among AML patients. To address
this question, I repeated once more a MAJIQ analysis to query for highly variable splicing
modules in curated list of well-documented NMD factors (Figure 3.5A-C). The most
variable splicing module within NMD factor genes represents the alternative first exon
usage of SMG1 transcripts. Instead of truncating the protein as is the case with the
insertion of PTC, alternative first exon usage could potentially change the function of the
encoded protein. Protein kinase SMG1, a phosphoinositide 3-kinase (PI3K)-like kinase,
phosphorylates UPF1 at multiple serine-threonine-glutamine ([S/T]Q) motifs in its Cterminal domain thereby activating UPF1-mediated NMD [150]. The use of an alternative
first exon in SMG1 is coupled with the use of a different 5’UTR, which can affect transcript
regulation and localization. Furthermore, the intron sequence between the first exon and
the alternative exon ~26 kilobases in length, suggesting the potential use of an alternative
promoter to initiate transcription at the alternative first exon. The second most variable
splicing event represents the alternative last exon inclusion of PYM1, which encodes a
protein that interacts with EJC components MAGOH and RBM8A. The alternative last
exon usage leads to switch a shorter isoform that also includes an entirely different 3’UTR
which may confer a point of regulation at the level of mRNA localization and degradation.
Additionally, it is thought that the N-terminus of PYM1 binds to both MAGOH and
RBM8A [151], thus the translation of a truncated peptide can potentially exert dominant
negative effects by sequestering active EJC complexes.
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Interestingly, I did not find any highly variable splicing modules within the gene
UPF1, which encodes the most essential factor required to disassemble the structured
messenger ribonucleoproteins actively undergoing degradation [152]. However, I do find a
highly variable splicing event in the gene UPF2 representing the inclusion of a cryptic
poison exon between exons 9 and 10 – which I termed exon 9b. The inclusion of poison
exon 9b is expected to functionally downregulate protein similar to the inclusion of poison
exon 12b in DHX34. Interestingly, the inclusion of UPF2 exon 9b is present at steady state
levels (~35%) in CD34 normal donors with a variability higher than the threshold defined
in Figure 2.2, alluding to a potential feedback loop that may be regulating the expression
of the encoded protein. Furthermore, it appears that the majority of the PENN-AML
patients actually have significantly less inclusion of UPF2 poison exon 9b compared to
CD34 normal cells. UPF2 is an adaptor protein that brings together UPF1 and UPF3 to
elicit NMD and there is contradicting evidence that UPF2 is dispensable for the successful
NMD. Thus, the finding that UPF2 poison exon 9b is significantly less included in AML
patients compared to normal donors is intriguing, as it alludes to the idea that at least a
subset of patients may depend on increased of UPF2 protein expression for AML blasts
cell viability.
Additionally, I find splicing variations in UPF3A and not UPF3B. Specifically, the
splicing variation in UPF3A represents the skipping of exon 8 which results in a frameshift
alteration and creates downstream PTCs and is expected to functionally downregulate the
encoded protein. The UPF3 protein is encoded by two paralogs: UPF3A and UPF3B.
UPF3A serves as a weak NMD factor and NMD repressor by sequestering UPF2 from the
NMD machinery, while UPF3B is a NMD branch-specific factor that directly binds the EJC
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and stimulates NMD [153]. Therefore, it appears that highly variable splicing events in AML
patients are targeting NMD factors with auxiliary-type involvement in NMD activity,
instead of targeting essential regulators such as UPF1. This suggests that the AML blast do
not tolerate splicing alterations to essential genes, and that they may be adapting the
balance of the NMD-splicing regulatory axis to favor cell survival.

Figure 3.5 – Highly variable splicing modules in NMD factor genes. (A) List of
NMD factor genes used in the extended analysis of splicing variations. (B) Heatmap
showing the variance of highly variable splicing modules (Red arrows depict the splicing
modules plotted in panel C) (Variance threshold cutoff is the same used in the initial
analysis shown in Figure 2.2) (C) Violin plots showing PSI distribution of the most
variable splicing modules in NMD factors across AML cohorts and CD34 normal donors.
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Discussion
Collectively, the analyses discussed in Chapter 3 elucidate the pervasive role of
alternative RNA splicing in regulating successful gene expression. Specifically, I discover
a significant number of patients with higher inclusion of poison exon 12b in DHX34
transcripts Furthermore, I demonstrate the function of this poison exon in regulating the
successful expression of this gene through a previously undocumented feedback loop. I
successfully inferred a subset of potential target substrates of DHX34 NMD activity using
data from an independent study of NMD factors that had not directly tested for DHX34
targets. I experimentally confirmed using a CRISPR-engineered cell line model that the
inferred target substrates of DHX34 NMD activity were indeed altered upon forced
inclusion of poison exon 12b. The DHX34 target gene substrates include transcripts
encoding regulators of chromatin, such as CHD2 and METTL22, and thus present a
potential alternative avenue for further dysregulation of chromatin structure within AML
blasts. Therefore, NMD inactivation that leads to the over expression of oncogenes and/or
the perturbation of functional transcript expression of tumor suppressors may be an
alternative route that supports AML disease pathology.
Interestingly, the inclusion of DHX34 poison exon 12b seems to be present at
steady state levels (~50%) in the CD34 donor cohort, suggesting its potential utility in
regulating DHX34 protein expression as part of normal cell physiology. Of note, essential
poison exons encoded within the genome tend to show higher conservation scores around
the sequence boundaries of the particular exon occurring within the intronic sequence,
however, that is not the case for cryptic exon DHX34 exon 12b, where there is absolutely
no conservation between phylogenetic species. Questions still remain regarding the
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particular regulators of poison exon 12b inclusion as well as the NMD factors that may
target DHX34 transcripts themselves for decay. Motif analysis of the exon sequences of
DHX34 exon 12, exon 12b and exon 13 as well as flanking intronic sequences reveal several
UGGYUG motifs peppered across exons 12 and exon 12b. Furthermore, I also observe a
large AGRCCANCAA motif within the boundaries of each of the three exons as well as
several instances of AAG-rich sequences, suggesting potential competitive regulation by a
poly-purine binder.
To understand the pervasiveness of alterations to the NMD pathway within AML
patients, I expanded my analysis to include known regulators of NMD. I find that a subset
of NMD factors indeed harbor highly variable splicing events that are predicted to
functionally disrupt NMD. Although there is evidence of the coupling of splicing variations
and NMD, the highly variable splicing events within NMD factor transcripts that I describe
in the AML patients are undocumented. The alternative splicing events in SMG1 and PYM1
directly affect proteins involved in UPF1’s interaction with the EJC as well as its activation
via kinase phosphorylation. Additionally, the significant reduction of UPF2 poison exon
9b inclusion is predicted to increase the availability of UPF2 protein in the AML blast cells.
Similarly, the reduction of UPF3A exon 8 skipping is also predicted to increase the
availability of UPF3A protein, a known repressor of UPF2. Thus, the splicing events in
UPF2 and UPF3A suggest that AML blast cells may rely UPF2 activity to sustain their
altered cellular program. Collectively, my findings are consistent with the widely accepted
coupling of alternative splicing and NMD activity in the cell and pose new questions as to
how the cancer cell may be leveraging NMD dysregulation via the plasticity of alternative
mRNA splicing to promote oncogenicity and cell viability.
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Conclusions
The work presented throughout this dissertation underscores the contribution of
alternative RNA splicing to the functional dysregulation of particular genes that typically
harbor mutations associated with the development and progression of AML. As discussed
in Chapter 1, AML is an aggressive type of hematologic cancer characterize by the clonal
proliferation of poorly differentiated myeloid progenitor cells. AML blasts usually harbor
chromosomal rearrangements, cytogenetic abnormalities and gene fusions that confer
aggressive oncogenic capacity. However, it is now understood that about half of AML
patients have a cytogenetically normal karyotype and that genetic mutations such as single
nucleotide substitutions and small tandem duplications account for the majority of driver
molecular lesions in AML. Regardless of the significant progress in the study of AML, the
genetic basis of this disease remains to be fully understood given that mutations in
individual AML-associated genes are lowly penetrant across the patient population. In
particular, most AML-associated genes are mutated in less than 10% of patients, with only
three genes (FLT3, NPM1, DNMT3A) harboring mutations in more than 20% of the AML
patient population. Furthermore, the patient population is significantly heterogeneous
because most patients harbor mutations in more than 1 particular gene, and these
mutations are expressed in complex patterns of co-occurrence and mutual exclusivity.
Importantly, as I have thoroughly discussed throughout this dissertation, genetic
mutations are not the only way to dysregulate a gene. Specifically, my study highlights that
alternative pre-mRNA splicing is a gene regulation mechanism capable of disrupting
protein function that is largely underappreciated in the study of AML and of cancer. Of
note, mutations in splicing factor genes are common in myeloid malignancies overall and
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have been shown to induce different disease phenotypes according to cellular context.
While a handful splicing factors (U2AF1, SRSF2, SF3B1, and ZRSR2) are among the socalled “commonly mutated” genes in AML, these also are present in less than 10% of
patients and no common pattern of splicing dysregulation has been associated with these
mutations. Therefore, the study that I have performed for this dissertation aimed to
uncover variations in pre-mRNA splicing that were not only common across the AML
population but also independent of any known splice factor mutation.
Alternative mRNA splicing outcomes can lead to the inclusion of exonic sequences
that result in either the insertion of an in-frame PTC or the production of a de novo PTC
via frame-shift alterations. However, although the potentially deleterious effects of
dysregulated mRNA splicing are acknowledged in the literature, no particular study had
focused on identifying splicing variations strictly within genes known to be commonly
altered by genetic mutation in AML. To address this gap, I leveraged the use of poly(A)selected mRNA-sequencing data to perform a MAJIQ high-throughput analysis of
alternative splicing for a set of 70 AML-associated genes. I built an extended pipeline to
processes MAJIQ splicing quantification data into distinct splicing modules, which is a
data feature that I developed to facilitate filtering and dimensionality reduction in the
analyses presented within this dissertation. Specifically, MAJIQ quantifies and models
splicing events in terms of local splicing variations (LSVs), and these LSVs can sometimes
overlap as well as point to the same molecular event. This merited the development of a
new feature, namely splicing modules, that allowed me to combine overlapping LSVs and
junctions into a distinct splicing event and produce relevant statistics. For each splicing
module, the junction with the highest variance in percent spliced in (PSI) represented the
intrinsic variability of the splicing choices of a particular event across AML patients.
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To increase the likelihood of identifying functionally relevant splicing events, as
well as to underscore the molecular heterogeneity of AML, I focused my analysis of on
those splicing modules with the highest variability across the PENN-AML patients
themselves. After identifying the most highly variable splicing modules present in the
PENN-AML, I compared the intensity of the splicing module variances with that of a
cohort of CD34+ normal myeloid donor cells as well as the large and independent
BeatAML patient cohort (See Chapter 2, Figure 2.3). The quantification of splicing
modules in CD34+ donors revealed that these cells normally express a tight range of
splicing decisions within this particular cell type (Figure 4.1). This suggests that healthy
cells may be normally regulating these splicing events as part of intrinsic cell functions.
Importantly, in most of the 40 highly variable splicing modules, the absolute change
between the mean PSI for a module m in PENN-AML vs CD34+ was less than 20%. This
highlights the underlying heterogeneity of AML because a large proportion of patients
express significantly different PSI in the splicing of events that on average may appear to
be relatively unchanged.
Strikingly, the analyses performed in Chapter 2 uncovered that most of the highly
variable splicing modules of interest are also highly correlated between themselves, which
is suggestive of biological co-regulation (Figure 4.1). Specifically, I explored the
relationship between splicing events, by producing a pairwise matrix of Spearman rank
correlations between splicing modules and reordered the features by hierarchical
clustering analysis which facilitated the identification of those splicing modules that
exhibited the highest degree of co-regulation. This finding is of particular importance
because it suggests that the penetrance of one particular splicing variation affecting an
AML-associated gene can be coupled with the perturbation of multiple other AML-
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associated genes via altered splicing. Furthermore, the co-regulation of the splicing
modules found in PENN-AML was equally observed within the BeatAML patient cohort,
suggesting that this pattern is representative of underlying biological mechanisms of AML
pathology at large.

Figure 4.1 –PSI distributions of the 23 highly co-regulated splicing modules
across AML patients and CD34 normal donors. The top panel is a violin plot of
showing the pooled distribution of PSI for the coregulated splicing modules across PENNAML and BeatAML patients. The bottom panel is PSI distribution in CD34 normal donor
cells of the same modules in top panel. The violin plots are ordered based on the
hierarchical clustering dendrogram displayed on the top panel. The line whiskers within
the distribution plots represent the mean PSI ± 1 standard deviation for each splicing
module in each panel. The normal range in splicing of CD34+ cells was plotted in both
panels to show how many AML patients are significantly deviating from the levels
0bserved in these healthy cells.

Critically, in the present study I experimentally characterized via radiolabeled RTPCR and Western blot analyses a set of highly variable and co-regulated splicing events
that result in the reduction of full-length protein expression facilitated by the inclusion of
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a PTC. In the case of the gene EZH2, I discover that the skipping of exons 11 and 12 results
in a frameshift alteration that leads to the production of a PTC in the upstream exon. This
particular splicing event involves more than two junctions, and thus is categorized as a
complex splicing event that can only be quantified by computational frameworks, such as
MAJIQ, that leverage the modeling of LSVs. Additionally, I find within EZH2 transcripts
the inclusion of exon 9b, which introduces an in-frame PTC and has been previously
described in the literature to induce NMD via UPF1-sensitivity assays [92]. The inclusion
of exon 9b seems to be present at steady state levels of around 25% within CD34 normal
donors, and the high degree of sequence conservation within the intronic sequence
suggests that this particular event is a functionally relevant molecular switch.
Furthermore, the skipping of EZH2 exon 11 and 12 was not correlated with the inclusion
of exon 9b, suggesting that there are distinct underlying mechanisms by which the splicing
of these exon sequences is altered.
The identification of a highly correlated set of splicing variations raises questions
regarding the mechanism by which these are manifested within the AML blasts. In my
analysis, I identify splicing variations in transcripts encoding splice factors themselves,
namely ZRSR2 and U2AF1, which are highly correlated with the skipping of EZH2 exon 11
and 12. Specifically, I found that an alternative last exon facilitates the transcription of a
short isoform of ZRSR2 which consequently downregulates the expression of full-length
protein – across the patients who are then also deficient for EZH2 protein. In contrast,
U2AF1 protein expression are seen unaffected by the variation in exon 3 to exon 3’ splicing
that I uncover within AML blasts, presumably because although the event itself is highly
variable, it is only functionally present in less than 25 % of transcripts. The functional
downregulation of a splicing factor via an autoregulatory alternative splicing could be
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regulating the splicing modules in question. To test this, I depleted ZRSR2 and U2AF1
factors in MV411 cells; however, this did not recapitulate the splicing patterns observed in
of AML cells.
The co-regulated splicing events in question could be a result of a more complex
combination of molecular alterations that are not recapitulated by only the depletion of
U2AF1 and/or ZRSR2. In light of this, I analyzed the sequence regions around the highly
variable splicing modules to find evidence of regulatory mechanisms, and I found an
enrichment for AAG-repeats. Interestingly, I also found a very strong correlation between
gene expression of SRSF1, a well-known RBP with a preference for poly-purines, and the
PSI values of most co-regulated splicing modules. However, knockdown of SRSF1 was also
not sufficient to induce the co-regulated variations in splicing observed for EZH2 and
ZRSR2. Therefore, there is still the unanswered question regarding the mechanisms that
may be collectively leading to the manifestation of the co-regulated variations in mRNA
splicing within AML-associated genes that I have catalogued across AML patient cohorts.
To further explore the role of alternative splicing in dysregulating key genes within
AML blasts, I describe in Chapter 3 an expanded analysis that includes a set of 20 genes
recently published to have an association with germline cases of AML After using the
MAJIQ pipeline to query splicing modules within this additional set of genes, I found of
particular interest the inclusion of poison exon 12b within the gene DHX34. Prior work
had failed to find enrichment of somatic mutations within DHX34 outside of two instances
of familial AML and thus, this is the first study to inquire about reduced function of
DHX34 protein through alternative splicing within AML blasts. Although inclusion of the
DHX34 poison exon doesn’t strongly correlate with the main cluster of the other splicing
modules, some of the patients that had higher skipping of EZH2 exon 11 and 12 also had
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noticeably higher inclusion of DHX34 poison exon. Therefore, the reduced efficiency of
NMD that results from the inclusion of DHX34 poison exon may explain the increased
accumulation of at least some of the splicing events that I describe in my study. To test the
effects of inclusion of DHX34 poison exon 12b I inferred potential NMD targets, and I
experimentally validated using CRISPR gene editing that forced inclusion results in the
increased abundance of target transcript substrates (CHD2, PARP6, METTL22 and
WHAMM). These genes have demonstrated roles in important cell functions such as
chromatin regulation and cell cycle progression; thus, the dysregulation of the respective
gene transcripts may promote oncogenicity of AML blasts. Therefore, this analysis
represents the first study of regulation of DHX34 protein expression via inclusion of
poison exon 12b and for the first time identifies that this exon is included in significantly
higher proportions across the population of sporadic AML patients.
RNA-seq data is rich information that can be leveraged to decode multiple layers
of biological regulation. The aligned short reads can be further processed to determine
small nucleotide variations within RNA transcripts. An analysis of genetic mutation
frequencies in the PENN-AML cohort using the RNA-seq method confirmed mutations at
known target loci of interest (Figure 4.2). The frequency of mutations identified for the
PENN-AML cohort slightly differs from that of the broad AML population due to an
overrepresentation of FLT3-ITDs and FLT3 mutations as well as an underrepresentation
of mutations in genes such as DNMT3A. Due to intrinsic methodological limitations, more
work needs to be done to accurately derive these genetic variants from the RNA-seq data,
however, the data is sufficient to provide an idea of the level of dysregulation that may be
attributed to genetic mutation alone. Importantly, using the same RNA-seq data we can
account that for most of the AML-associated genes, changes in alternative splicing
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noticeably increases the proportions of AML patients with molecular alterations (Figure
4.2). Interestingly, although there are mutations in splicing factors SRSF2 and SF3B1,
MAJIQ did not quantify any variability at the level of splicing for these genes.
Furthermore, analysis of DHX34 sequence results in the quantification of uncatalogued
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Figure 4.2 – Proportion of PENN-AML patients with molecular alterations
within AML-associated genes. The black bar plot shows proportion of patients with
genetic mutations quantified from the RNA-seq reads at particular loci of interest.
Specifically, the proportion of FLT3 mutations also includes the proportion of FLT3-ITD
which were determined via standard genotyping analysis. The red bar plot shows the
proportion of additional patients that have molecular alterations in this case resulting
from alternative RNA splicing. The proportion of patients with altered splicing was
derived from the number of patients that expressed significantly different levels of a
particular splicing module when compared to the normal range in splicing found in CD34+
donor cells. The bar plot is sorted by decreasing frequency of genetic mutation followed
by decreasing frequency of alternative splicing.

The identification of DHX34 mis-expression in AML due to splicing not only
underscores the importance of assessing splicing as a contributor to gene dysregulation in
AML, but also highlights the potential importance of regulation of NMD to the pathology
of this cancer. Therefore, building off of this particular finding and reasoning, I queried an
additional set of splicing variations within NMD factor genes, in an effort to further
understand the penetrance of functionally dysregulated NMD across the AML population.
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I found significant variation in splicing of transcripts encoding core components of the
decay inducing complex such as SMG1, UPF2 and UPF3A. Interestingly, I did not find
variable splicing within transcripts encoding the most essential NMD factor, UPF1,
presumably because alterations to the expression of this particular protein may not be
tolerated by the AML blasts. Furthermore, this analysis also uncovered that some of the
splicing events within NMD factor genes are strongly correlated with the splicing of
particular AML-associated genes. Overall, my analyses and my findings further couple the
regulation of NMD to alternative mRNA splicing and provides a deeper insight of the
contribution of NMD to the pathology of AML and of cancer.
Perspectives & Future Directions
Acute myeloid leukemia is an aggressive and highly heterogenous form of
hematologic cancer. There have been extensive studies regarding the genetics of AML,
however, for at least half of the patient population, the molecular basis of the disease
remains to be fully understood. As discussed in Chapter 1, there are a number of distinct
genomic lesions that have been found within AML patients, leading to substantial disease
heterogeneity. The central question motivating the work performed in this dissertation is
whether mRNA splicing variations are an unaccounted source of molecular heterogeneity
capable of leading to altered protein function. The mechanisms and outcomes of
alternative splicing of individual transcripts are relatively well understood and the body of
work presented throughout this dissertation further contributes to the knowledge base of
alternative mRNA splicing as an essential contributor of functional gene expression.
Through my query of splicing variations, I was able to identify that many more AML
patients harbor molecular alterations that functionally dysregulate particular essential
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proteins than what was normally being accounted for by just looking at activating and
deleterious genetic mutations. Thus, my findings strongly underscore that alternative
mRNA splicing needs to be quantified in the process of fully profiling the molecular basis
of individual patients suffering from AML. Furthermore, I provide through my work a
robust catalogue of alternative pre-mRNA splicing variations and I elucidate at subset of
the most interesting events. However, more work needs to be done to fully understand the
dysregulation of mRNA splicing in AML.
Critically, the depth and robustness of the high throughput splicing quantification
analysis was facilitated by the MAJIQ computational framework and its use of the LSV
concept. Other splicing quantification algorithms have intrinsic limitations that would
have prevented me from properly identifying the more complex sets of splicing variations
that I described in my study. As previously discussed, many of the high throughput
splicing quantification algorithms methods that were available at the time of initiating my
studies only analyzed known and annotated transcript isoforms. In contrast, MAJIQ
supplements known transcripts with de novo junctions inferred from the RNA-seq data.
Although I focused on elucidating the significance of DHX34 exon 12b inclusion, which is
a simple binary splicing event, most of the splicing modules that I describe include the use
of unannotated cryptic exons as well as choice between more than 2 splicing choices.
Therefore, the use of LSVs as well as the detection of de novo splice junctions by the
MAJIQ framework is currently the most ideal tool in the field to generate a robust
transcriptomic profile that accurately captures the complexity of the mRNA splicing
choices elicited by cancer cells.
Most splicing quantification algorithms rely on a differential model that requires
first the definition of a normal control. In contrast, the MAJIQ-PSI algorithm calculates
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empirical distributions of junction usage across every single RNA-seq sample individually,
and therefore facilitates the N-of-1 approach that is needed to study a highly heterogenous
disease such as AML. I emphasize that I first identified splicing modules across each of the
PENN-AML patients individually, and afterwards I compared the behavior of these
splicing modules across the larger BeatAML cohort as well as the cohort of CD34+ healthy
donor cells. Thus, the MAJIQ splicing quantification algorithm produced a catalogue of
mRNA splicing events, that includes those events with usage of junctions that is highly
variable across PENN-AML patients, as well as those events with junction inclusion that
is highly constitutive across patients. The robustness of this approach allowed me to go
one step further in my analyses, and thus quantify and experimentally validate rare
splicing events present only in 1 patient that are also expected to have a deleterious effect,
which was the case of the skipping of exon 9 in ZRSR2 (See Figure 2.6). These particular
rare splicing events are ignored if I were to perform differential comparison of grouped
AML patients vs. CD34+ normal donor cells, which is the case of most high-throughput
studies of splicing in AML.
Alternative splicing is naturally coordinated by RBPs that are capable of binding
to multiple distinct mRNA transcripts and thus facilitate altered splicing of multiple target
genes. Not surprisingly, recent efforts by other research groups have been directed more
towards studying the coordination of alternative splicing networks by leveraging the use
of short-read mRNA-sequencing data. Concordant with the field’s efforts, the particular
analysis that I have performed in this dissertation aims to provide a pipeline for the
identification of co-regulated splicing events supported by the validation of such events in
AML blasts. Specifically, the bioinformatics pipeline designed for this study predicted the
co-occurrence of splicing events in EZH2 and ZRSR2 within the patient-derived AML
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blasts, which we successfully validated via radiolabeled RT-PCR and western blot analysis.
While the signature of co-regulated splicing events is particularly striking, more
experiments should be performed to elucidate the mechanism by which this is manifested
across AML patients. In particular, it proved to be rather difficult to recapitulate these
splicing events in cell lines of leukemic origin. Transient knockdown of splice factors is
difficult because the cell typically upregulates the expression of splicing factors to
compensate for the lack of functional protein. Thus, an alternative approach could be to
force the use of ZRSR2 exon 3b and SRSF1 poison exon 4 using CRISPR, and thus force
the expression of the truncated isoforms and test for downstream changes in gene
expression and alternative splicing.
The occurrence of multiple co-occurring splicing variations poses the question as
to how the cell can adapt to support such a perturbed molecular profile, and if these
splicing events are associated with a particular outcome. One particular splice factor can
regulate hundreds of distinct splicing events, each of which may be contributing at varying
degrees to the oncogenicity of AML blasts. The widespread effects of dysregulated splicing
somewhat mirror the molecular two-hit model that has been historically proposed in AML,
where a particular myeloid cell needs to have a block in differentiation as well as an
activation of proliferation to elicit clonal expansion [154,155]. Specifically, the original
concept of the “AML two-hit model of pathogenesis” was limited to the alterations of genes
via genetic mutations and not via alternative mRNA splicing. As I have shown through my
work, particular AML patients have a significant functional downregulation of multiple
key proteins via dysregulated alternative mRNA splicing. I emphasize that the results of
my studies contribute to the molecular profiling of an heterogenous AML population, as
well as to the elucidation of mechanisms that may be potentially driving the oncogenicity
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and pathology of AML blasts. Future studies should focus on understanding the molecular
burden of the splicing events that I have identified throughout my studies.
Both EZH2 and ZRSR2, as well as other AML-associated genes, harbored multiple
distinct splicing variations that were un-correlated, which underscores the complexity of
multiple splicing decisions within the same transcripts that can affect the expression of
the respective gene. Furthermore, I note that uncorrelated variable splicing modules
within the same gene transcripts appear to result in the same loss- or change-of-function
effect, but through distinct avenues. The functional loss of EZH2 via skipping of exons 11
and 12 is expected to reduce cellular H3K27me di- or tri-methylation levels which
consequently would de-repress the expression of EZH2 target genes. I specifically did not
probe for downregulation of H3K27me di- or tri-methylation levels because of limited
sample availability of the patient AML blasts. However, there is functional evidence that
inclusion of EZH2 poison exon 9b, which is uncorrelated with the skipping of exon 11 and
12, leads to the a hypomethylated state [92]. Thus, future analyses should include
developing multivariate models that capture the distinct avenues that functionally
downregulate a particular AML-associated gene. Specifically, an integrative model of
molecular lesions that functionally downregulate EZH2 protein expression and activity
should at least include genetic mutations such as D185H, alternative skipping of exon
11/12 and alternative inclusion of exon 9b. It remains a question as to which particular
method is best suited to integrate fundamentally different data sources that represent
distinct layers of biological regulation. However, ideally a multivariate regression model
representative of EZH2 functional downregulation should be at least be predictive of
dysregulation of known EZH2 target genes.
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This body of work is also the first to describe the inclusion of DHX34 poison exon
12b as a gene expression regulatory mechanism. The significant increase of inclusion
within AML patient-derived blasts is suggestive of the need for the cancer cell to
functionally downregulate this particular gene to sustain oncogenicity. Furthermore, the
inclusion of this exon in 50% of DHX34 transcripts expressed in CD34+ donor cells
suggest that this exon may be included as part of intrinsic regulatory mechanisms. As
discussed thoroughly in Chapter 3, the DHX34 protein is involved in promoting NMD,
and functional loss of this gene causes a significant increase in the abundance of target
transcript substrates. The increased number of transcripts within the AML blasts is
expected to promote cellular stress and interfere with RNA-RNA and RNA-protein
interactions, which are essential for successful gene expression and regulation.
The role of NMD in carcinogenesis remains somewhat contradictory and unclear.
Most studies of cancer focus on the role of NMD in regulating PTC-inducing mutations in
oncogenes and tumor suppressor genes, rather than looking at downregulation of the
NMD pathway per se. Not surprisingly, tumor-suppressor genes (for example BRCA1,
TP53, WT1) are characterized by harboring more NMD-inducing nonsense mutations
relative to oncogenes, which often contain missense mutations [156]. This highlights the
crucial role of NMD in preventing the cell from translating truncated tumor suppressor
transcripts and thus protecting cells from malignant growth. Interestingly, inactivating
mutations in UPF1, UPF2, SMG1 and SMG6 are lethal, underscoring the essential role of
NMD in normal cell development [157,158]. Specifically, UPF1 NMD activity has been shown
to degrade particular pro-apoptotic factors so that cells avoid undergoing apoptosis [159].
Furthermore, during regulated apoptosis, caspases cleave the UPF1 and UPF2 proteins to
shutdown NMD, highlighting a regulatory feedback loop between the suppression and
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promotion of apoptosis [160]. This mechanism is conserved in human cells and likely helps
to explain why NMD has been found to be essential for embryonic viability. However, this
contradicts the observed inactivation of NMD in some tumors, suggesting that cancer cells
may adapt to circumvent the consequent upregulation of pro-apoptotic signals that are
targeted by NMD.
The loss of NMD pathway activity is expected to increase the burden of aberrant
transcripts in the cell. NMD factors interact with the EJC to define ‘prematureness’ of stop
codons, and normal transcripts escape NMD because all of the EJCs are typically
deposited upstream of the stop codon, permitting the ribosome to displace them. In
contrast, an aberrant transcript harboring a stop codon in a premature position will
typically have at least one EJC downstream of the PTC, thereby triggering NMD. To keep
the levels of physiological NMD targets constant, the efficiency of NMD itself is tightly
regulated. Consistently, there is evidence of NMD factors being targeted themselves by the
NMD pathway as a result of regulated alternative splicing. The persistence of aberrant
transcripts within the cancer cell due to NMD inactivation may result in de novo RNARNA and RNA-RBP interactions that are likely capable of promoting widespread changes
in gene expression regulation and RBP activity.
Specifically, non-coding RNAs are key posttranscriptional regulators of diverse
cellular functions and cell fate determination, including hematopoiesis. Over the past
several years, studies have recognized the potential of long non-coding RNAs (lncRNAs)
and short micro RNAs (miRNAs) acting as either tumor suppressors or oncogenes
depending on the targeted gene regulatory context [161;162]. As discussed in Chapter 1,
distinctive miRNA profiles have been associated with subtypes of AML defined by
cytogenic profiling [64], and loss of distinct microRNAs have been shown to lead to
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leukemia in mouse models [163]. Therefore, the increased accumulation of transcripts due
to NMD dysregulation in AML blast cells is presumably capable of sequestering important
microRNAs and potentially lead to the gene dysregulation leukemogenesis. More work
needs to be done to determine the molecular burden of NMD inactivation in the network
activity of non-coding RNAs. However, mapping non-coding RNAs to predicted target
sequences within AML-associated gene transcripts disrupted by alternative splicing may
provide an idea of the effects of increased competitive endogenous RNAs across the AML
patient population.

Figure 4.3 –Model of oncogenic stimulus promoted by dysregulated mRNA
splicing. A an heterogenous pool of gene isoform transcripts is present within a cell at
any given time. Altered splicing patterns may arise from changes to signal transduction as
well as from mutations in splicing factors. The altered splicing patters increase the
synthesis of non-productive transcripts as well as differential spliceoforms that translate
distinct peptides. A downregulation of NMD presumably allows the persistent occurrence
of non-functional transcripts. Collectively, the synthesis of these altered transcripts leads
to a loss of functional gene expression that feeds back into the regulation of mRNA splicing
to augment the pro-tumorigenic signal. Altered splicing patterns that result in loss- and
change-of function effects presumably increase the proliferative capacity of cells while
maintaining the differentiation blockade characteristic of AMLs, resulting in aggressive
disease progression.
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On a different note, many gene mutations that have been correlated to AML do not
cause loss-of-function. For example, AML-linked genetic mutations in FLT3 and BRAF
cause gain-of-function, while mutations in U2AF1 and ASXL1 alter protein function in
ways that remain to be fully understood. While I have focused this study on splicing
variations that introduce premature stop codons and thus reduce protein expression and
function, several of the highly variable splicing modules I detect in the AML patients cause
internal in-frame changes to the open reading frame or alter the N- and/or C-terminus of
the encoded protein (Table 2.1). Of note, for over half of the genes that harbor gain- or
change-of function genetic mutations in AML as well as highly variable splicing modules,
the splicing is predicted to change the function of the protein rather than introduce a
premature termination codon. This correlation suggests that these in-frame splicing
variations may also phenocopy genetic mutations, as I have observed for the loss-offunction mutations. However, more work is required to fully elaborate the functional
consequences of these in-frame splicing variations and compare their effect to genetic
mutations in the same genes. An immediate experiment would involve again generating
CRISPR models to test the effect of forced splicing in downstream functional gene activity
similar to the experiments performed for DHX34 poison exon 12b inclusion.
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Closing Remarks
Through my work I aim to motivate larger studies of AML with clinically annotated
datasets to determine if splicing patterns correlate with chemotherapeutic response
and/or overall survival. I emphasize that my findings highlight the critical importance of
assessing splicing patterns, in addition to genetic mutation and altered expression, in
determining the contribution of individual genes to disease phenotype. While I
demonstrate this to be true here for AML, I predict that assessment of splicing will be
similarly relevant to the study of gene dysregulation in most other diseases.
Despite its heterogeneity, one common feature of AML is its capacity to evade
programmed cell death and resist cytotoxic stimuli. Thus, 50% of elderly AML patients
will resist treatment and die within the first 6 months of diagnosis, and over 40% of young
patients relapse within 12 months of intensive chemotherapy [164,165]. The development of
therapies that target resistance factors and/or promote cell death has therefore been a
major focus of researchers and clinicians alike. The identification of splicing events that
are broadly mis-regulated across the AML population provides important candidates to
motivate further research aimed at testing the potential therapeutic relevance of
manipulating these AML-associated splicing events. In in at least one instance of cancer
preclinical models, pharmacological manipulation of mis-regulated exon inclusion
splicing events via antisense oligonucleotide treatment has been used to decrease tumor
growth [166].
In sum, short-read sequencing data originating from the RNA-seq methods used
in this study is rich in information that can be leveraged to decode multiple layers of
biological regulation. In this dissertation, I focused on surveying splicing variations across
AML-associated genes using RNA-seq data from AML patients. I experimentally validated
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splicing events in multiple distinct genes, and I uncovered new avenues by which AMLassociated genes get functionally downregulated in AML. Importantly. I began elucidating
how DHX34 gets dysregulated via poison exon inclusion, a mechanism that has not been
previously described in the literature. This finding then motivated the query of splicing
variations in NMD factor genes, a direct study that had not been performed, which
uncovered more interesting splicing events, and further coupled the activity of NMD with
the fidelity of splicing. To conclude, I emphasize the importance of quantifying alternative
splicing variations to paint a more accurate picture of the molecular pathology that drives
the development not only of AML, but also of other cancer types and of human diseases at
large.
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METHODS
AML Patient Samples
To construct the PENN dataset, AML blasts were first isolated from AML patients via sizeexclusion centrifugation apheresis or from peripheral blood on Ficoll gradients and stored
in the Penn Stem Cell and Xenograft Core at the University of Pennsylvania. To promote
the molecular characterization of a homogenous cell population, AML patient samples
were confirmed to be at least 90% blasts. CD34+ cells from PENN were isolated from adult
bone marrow by the Penn High Throughput Screening Core directed by Dr. Sara Cherry
and Dr. David Schultz. Total RNA was isolated from AML blasts by Trizol followed by
DNAse treatment and reprecipitation. Poly(A) selection, library preparation, and pairedend sequencing was performed by GeneWiz. Sample biospecimen data table was
published as part of Rivera et al 2021, Table S1) [38]
Poly-A mRNA Sequencing and Data Processing
High-throughput mRNA Sequencing files (.fastq) were pre-processed by Trim Galore
(https://github.com/FelixKrueger/TrimGalore) to trim short-read adapter sequences
from sample reads. Significantly larger datasets, such as the Beat-AML cohort were preprocessed with BBDuk (Decontamination Using Kmers, https://jgi.doe.gov/data-andtools/bbtools/). Pre-processed reads were then aligned to the human genome (GRCh38
Genome Reference Consortium Human Reference 38, GCA_000001405.15) using STAR
version 2.5.4b (https://github.com/alexdobin/STAR). The read-depth of RNA-Seq data
from the Penn cohort ranged from 50 to 200 million reads per sample, with read lengths
ranging from 75-150 nucleotides.
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RNA-seq reads mapping to 70 AML-related genes were used for downstream splicing
quantification analyses. The MAJIQ framework (https://majiq.biociphers.org/) [17] was
used to identify all local splicing variations (LSVs) within the defined sets of genes (e.g.
AML-related genes and NMD factor genes) across the PENN-AML cohort. An LSV is
defined as a single exon alternatively joined to more than one RNA segment. Junctions
involved in an LSV are quantified by Percent Splicing Index (PSI) values that represent
the relative fraction of poly-A selected mRNA transcripts in which the aforementioned
exon is joined to each of the alternative RNA segments. Variations in junction PSI
represent the occurrence of a particular splicing pattern across RNA-seq data. To
summarize our data, the quantified LSVs were used to construct splicing modules which
model the splicing events that are occurring within AML-related gene transcripts. For
every splicing module, the variance in PSI for junction j, or var(PSIj), across a particular
cohort was calculated and used to represent the variability of a splicing module across
patients in said cohort. Splicing modules with a var(PSIj) higher than one standard
deviation away of the mean var(PSIj) seen across patients in PENN-AML were deemed as
“highly-variable” and characterized in downstream analyses. Splicegraphs representative
of alternative splicing variation were visualized using VIOLA, an HTML5 web-tool. The
code repository of the pipeline developed for this study currently on Bitbucket and is
available upon request.
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Validation of Patient Donor Cohorts
Splicing modules found in the PENN-HTSC cohort were also queried within data from an
independent cohort of AML patients and a healthy myeloid donor cohort. A total of 444
RNA-seq files from AML patients were downloaded from the Beat-AML study [95].
+
Moreover, patient RNA-seq files from a cohort of CD34 cells isolated from 17 healthy
myeloid donors were downloaded from Leucegene (https://leucegene.ca/). RNA-seq data
was processed as described above. For Western blots and RT-PCR, new aliquots of cells
from the same patient collection were thawed and viable blasts harvested for RNA (Trizol)
and western blot (RIPA lysis buffer).
RNA-seq Single Nucleotide Variant Calling
Patient RNA-seq files were subjected to base quality recalibration, a data pre- processing
step that detects systematic errors made by the sequencer when it estimates the quality
score of each base call (https://software.broadinstitute.org/gatk/). Recalibrated RNA-Seq
reads were visualized within the Broad Institute Integrative Genomic Viewer (IGV_2.6.3).
Clinically relevant genomic regions for AML-genes were provided by the Penn Center for
Personalized Diagnostics (CPD). Single nucleotide variations (SNVs) for each AML patient
within clinically relevant regions were called from their respective RNA-seq reads. I also
screened for other known SNVs that have been previously tied to AML pathology. SNVs
were required to be evidenced a sequencing depth larger than 10 reads.
Gene Expression and Isoform Measurements
Transcript-level quantification of gene expression was estimated from the RNA-seq data
using

Salmon

quasi-mapping

algorithm (https://combine-lab.github.io/salmon/).
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Effective counts library sizes were computed using the edgeR package to account for
composition biases between samples. Transcript quantification was normalized to genelevel reads per kilobase per million (RPKMs) and transformed to a measure of relative
gene expression (log2RPKM) in downstream analyses. Variance of relative gene
expression associated with batch effects was regressed out of our transcriptomic models
using the ComBat framework (https://rdrr.io/bioc/sva/man/ComBat.html).
Statistical Analyses
Splicing modules:
We plotted the distribution of splicing module variances across the cohorts and assed
statistically significant differences between the mean splicing module variances using
Student’s t-test. A pairwise analysis between the PSI values of each “highly-variable”
splicing module generated a dissimilarity matrix of Spearman’s rho correlations. To
account for the unknown vector directionality of splicing modules, I used the absolute
value of the Spearman’s rank correlation coefficient in our pairwise dissimilarity matrix.
Complete linkage hierarchical clustering of the Spearman rho dissimilarity matrix was
used to cluster highly correlated splicing modules into a distinct group. Splicing modules
grouped together via the hierarchical clustering algorithm were used to shed light into
molecular co-regulation of alternative splicing. Pearson R test was used to determine the
correlation coefficients between splicing modules and gene expression vectors.
Correlation of DHX34 splicing with NMD target expression:
We used a common threshold of p-value ≤ 0.05 on the correlation between DHX34 exon
12b inclusion ratio and the transcript abundance of NMD target substrates on both
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datasets. The threshold over the p-value rather than correlation coefficient was used to
account for the large difference in sample sizes in the two datasets. The above test based
on random permutation of the observed expression values allows us to detect significant
correlations while accounting for sample sizes. However, it is still possible that DHX34
expression values will significantly correlate with many genes in general. In order to assess
the enrichment of significance correlation between DHX34 and the previously reported
NMD targets I correlated DHX34 exon 12b inclusion with the transcript abundance of a
set of 1000 random genes, and I bootstrapped the correlation results 1000 times, each
time picking a new set of random set of genes. For each gene set randomization, I
computed the number of correlations passing the above threshold in both datasets, which
in turn allowed us to assess the p-value of significantly positively and negatively correlated
genes in our original set of NMD targets using a one sample t-test as shown in Fig. 5E.
Cell Lines and CRISPR mutations
In vitro growth of MV411 (ATCC CRL-9591) and HL60 (ATCC CCL-240) myeloid cell lines
were by standard methods. Due to relative ease of transfection and basal level of DHX34
exon 12b inclusion, CRISPR mutations in DHX34 were done in the lymphoma Jurkat cell
line by Dr. Rakesh Chatrikhi, and grown as described in [167]. CRISPR mutations were
done

by

transfecting

cells

with

SpCas9-2A-GFP

(pX458

plasmid,

Addgene:

https://www.addgene.org/48138) containing templates for guide RNAs, together with the
repair template shown in Figure 3.4A. 48 hours after transfection cells were washed and
sorted for GFP+ cells. Single cells were cultured in 96 well plates for 3 weeks, expanded
and screened by PCR to identify modified clones. Primers used for genomic PCR were the
same as for RT-PCR shown in Table S2.
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Western blots, qPCR and radiolabeled RT-PCR
Radio-labeled radiolabeled RT-PCR was performed as previously described (30). Splicing
modules were amplified and validated experimentally using the primer pairs specified in
Table S2. For qPCR, total RNA was converted to cDNA via reverse transcription using
MMLV reverse transcriptase, followed by amplification using the Power SYBR Green PCR
Master Mix (Applied Biosystems) in a LightCycler® 96 Instrument (Roche Life Sciences)
at 55°C for 10 min, 95°C for 1 min, and then 40 cycles of 95°C for 10 sec and 60°C for 1
min. Primers targeting genes of interest were designed over splice junctions and spanning
regions of constitutive splicing. Amplicons were designed to be less than 200 bp in length.
Radiolabeled RT-PCR and qPCR primer sequences are published in Table S2 of Rivera et
al 2021 [38]. Antibodies used for Western blots were as follows: EZH2 (a kind gift from Dr.
Roberto Bonasio, UPenn), U2AF35 (Abcam catalog ab86305), ZRSR2 (Novus NBP157307), DHX34 (Novus NBP1-91832), Lamin B1(Abcam ab133741), and GAPDH (Abcam
ab128915).
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